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ABSTRACT OF DISSERTATION 
 
 
 
 
BIOERODIBLE CALCIUM SULFATE BONE GRAFTING SUBSTITUTES WITH 
TAILORED DRUG DELIVERY CAPABILITIES 
 
Bone regeneration or augmentation is often required prior to or 
concomitant with implant placement. With the limitations of many existing 
technologies, a biologically compatible synthetic bone grafting substitute that is 
osteogenic, bioerodible, and provides spacing-making functionality while acting 
as a drug delivery vehicle for bioactive molecules could provide an alternative to 
‘gold standard’ techniques. 
 
In the first part of this work, calcium sulfate (CS) space-making synthetic 
bone grafts with uniformly embedded poly(β-amino ester) (PBAE) biodegradable 
hydrogel particles was developed to allow controlled release of bioactive agents.  
The embedded gel particles’ influence on the physical and chemical 
characteristics of CS was tested.  Namely, the compressive strength and 
modulus, dissolution, and morphology, were studied. All CS samples dissolved 
via zero-order surface erosion consistent to one another. Compression testing 
concluded that the amount, but not size, of embedded gel particles significantly 
decreased (up to 75%) the overall mechanical strength of the composite. 
Release studies were conducted to explore this system’s ability to deliver a broad 
range of drug types and sizes.  Lysozyme (model protein for larger growth factors 
like bone morphogenic protein [BMP]) was loaded into PBAE particles embedded 
in CS matrix.  The release of simvastatin, a small molecule drug capable of up 
regulating BMP production, was also examined. The release of both lysozyme 
and simvastatin was governed by dissolution of CS.    
 
The second part of this work proposed a bilayered CS implant. The 
physical and chemical properties were characterized similarly to the CS 
composites above.  Release kinetics of directly loaded simvastatin in the shell, 
core, or both layers was investigated.  A sequential release of simvastatin was 
witnessed giving foresight of the composite’s tunability.  The sequential release 
of an antibacterial, metronidazole, loaded into poly(lactic-co-glycolic acid) (PLGA) 
particles embedded into the shell along with directly loaded simvastatin either in 
the shell, core, or both layers was also observed.  Through controlled release of 
bioactive agents, as well as a tunable layered geometry, CS-based implants 
have the potential to be optimized in order to help streamline the steps required 
for the healing and regeneration of compromised bone tissue. 
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Chapter 1:  Introduction 
  
Bone augmentation is often required prior to, or associated with, implant 
placement in the oral cavity.  With the limitations of many existing technologies, a 
biologically compatible synthetic bone grafting substitute that provides space-
making functionality while acting as a drug delivery vehicle for bioactive agents 
could provide an alternative to ‘gold standard’ techniques.  To begin, Chapter 2 
discusses the background of oral and maxillofacial bone augmentation, and 
conditions that would merit such an operation, such as the most common and 
destructive inflammatory disease of humans: periodontal disease.  The section 
discusses in further detail the current standard practices involved for treatment 
and bone regeneration.  Next, the discussion describes current advancements in 
bone graft substitutes, and the use of controlled local drug delivery for better 
treatment.  The chapter finishes by describing the three major specific aims of 
the research being presented in this dissertation.     
 The primary goal of this work was to develop a suitable synthetic bone 
grafting substitute that could be considered a promising alternative to the ‘gold 
standard’ use of autologous bone tissue.  Chapter 3 illustrates the process of 
development and characterization of a calcium sulfate (CS) / hydrogel composite 
scaffold.  The physical and chemical characteristics were investigated to 
determine if the introduction of poly(β-amino ester) hydrogel (PBAE) particles, 
intended for use as a drug delivery vehicle, would have an effect on the overall 
scaffold when embedded into CS.  Degradation, compressive strength, and 
morphology were examined.  This first segment finishes with a small pilot release 
study to demonstrate the controlled drug delivery potential of these CS 
composite implants. 
 To expand on the characterization of CS/PBAE composite implants 
presented in Chapter 3, the drug delivery potential was further investigated in 
Chapter 4.  The concept for this chapter was to show that the composites were 
capable of sustaining the release of a broad range of osteogenic drug types and 
sizes (i.e. larger proteins vs. smaller molecule drugs).  The rationale behind this 
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idea was to be able to tailor the device, whether a larger bone growth factor like 
bone morphogenetic protein or a small molecule such as simvastatin were to be 
needed.  Various loading methods were utilized (i.e. direct loading into CS or 
loaded within PBAE particles embedded into CS) to investigate what method 
would allow for sustained or controlled release of the drug.  Because directly 
loading drug into CS may have an impact on the structure of the composite, 
mechanical and degradation testing was also conducted. 
 Chapter 5 presents the development of a bilayered device capable of 
releasing multiple drugs sequentially.  Due to the fact that bone regeneration is 
slowed in the presence of bacteria following advanced periodontal disease or in 
any infected bony defect, the release of an antimicrobial followed by an 
osteogenic drug could allow for a more streamlined treatment.  This section 
starts out describing the similar testing methods performed in Chapter 3 to fully 
characterize the physical and chemical attributes of the bilayered composites as 
well as any effects of shell loaded poly(lactic-co-glycolic acid) (PLGA) particles.  
Next, the release of simvastatin was conducted with the drug loaded into the 
shell, the core, or both layers of the CS constructs.  To allow for further tuning of 
the implants, the shell to core volume ratio was altered to demonstrate how the 
release of simvastatin could be further delayed or prolonged from a given layer 
during dissolution.  The study concludes by investigating the sequential release 
of simvastatin directly loaded into calcium sulfate and metronidazole loaded 
PLGA particles embedded into the CS shell of the composite.   
 The development of CS-based composites with controlled release of 
bioactive molecules has the potential to greatly enhance the ability of these 
implants to become more effective bone graft substitutes.  The introduction of a 
layered geometry may further allow for bone graft substitutes to be optimized in 
order to help streamline the multiple steps needed to regenerate tissues, thus 
becoming a suitable competitor or even an alternative for the use of autografts. 
 
 
Copyright © Bryan Richard Orellana 2014  
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Chapter 2:  Background and Significance 
 
2.1. Oral and Maxillofacial Bone Augmentation 
Bone augmentation, commonly employed for craniomaxillofacial 
applications, is the build-up of new bone on an already compromised bony 
surface using a grafting material to restore proper function, aesthetics, or even 
provide a stable platform for the insertion of a prosthetic.  Currently around the 
world there is an increasingly high demand for functional bone grafts [1, 2].  Each 
year roughly 2.2 million bone graft procedures are performed worldwide with 
about half a million patients receiving bone defect repairs in the United States [1, 
3].  For dental rehabilitation of partially or totally edentulous patients, treatment 
with oral implants has become common practice in the last decades, with reliable 
long-term results [4].  However, unfavorable local conditions of the alveolar ridge, 
due to atrophy, periodontal disease and trauma, may provide insufficient bone 
volume which may render implant placement impossible or unstable from a 
functional and esthetic viewpoint [4-6].  Many different techniques have been 
considered for augmentation; osteoconduction through the use of a grafting 
material, osteoinduction through the aid of growth factors, bone distraction, or 
guided bone regeneration (GBR) where barrier membranes maintain space for 
which bone to regenerate [4, 7].  All of which have resulted in comparable long-
term implant survival [7].    
 
2.2. Periodontal Disease 
Periodontitis is one of the most common and destructive inflammatory 
diseases of humans, and is a leading cause of tooth mortality in adults [8, 9].  
This disease is a complex inflammatory infection affecting numerous tissue 
types, soft and/or hard, within the oral cavity, and is caused by a buildup of 
bacteria.  This buildup is usually due to the lack of proper personal oral hygiene 
administered by the patient and/or the absence of routine dental checkups.  In 
other words, this disease can be fairly easily avoided, but has the ability to form 
aggressively.  If left untreated the bacteria can form pockets of infection just 
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below the gum line allowing it to progress causing an innate immune response 
leading to localized inflammation [10].  This inflammatory condition can lead to a 
progressive destruction of periodontal tissues, namely alveolar bone, periodontal 
ligament, and root cementum [11, 12].   
There are many different pathogens and microorganisms that play a role 
in periodontal infections, some of which may be more prevalent than others.  For 
instance, the more significant pathogens associated with periodontitis are 
Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, and 
Bacteroides forsythus [9, 13-15].   These pathogens can be located in most areas 
of the oral cavity, but for the purpose of this research we are focusing on 
pathogens located in plaque.  According to Slots and Jorgensen, they describe 
dental plaque as a form of biofilm which is defined to be a sessile community of 
interdependent microorganisms organized within an exopolymer that is attached 
to solid surfaces [9].  If untreated, plaque will continue to build acting much like a 
dam forming a pocket where pathogens will be allowed to flourish.  This bacterial 
infection will cause a local inflammatory response.  At early stages this 
inflammation of the gums is also described as gingivitis, a very common 
infection, affecting 75% of American Adults [16].  According to David Cochran, an 
amplification of this initial localized response results in the release of an array of 
cytokines and other mediators leading to the propagation of inflammation through 
the gingival tissues [10].  If still allowed to proliferate, the chronic inflammatory 
effect will begin to break down connective tissue and ultimately alveolar bone 
[10].  Although periodontitis has been found to be reversible, the extensive loss 
of bone tissue has the potential to lead to the loss of teeth requiring extensive 
and potentially very expensive regenerative surgeries [9]. 
Progression of this magnitude will ultimately lead to the loosening or 
complete loss of teeth.  Periodontal disease is also associated with many 
different systemic effects, such as coronary artery disease, stroke, and even 
diabetes; all of which risking the increase of heart attack and/or other serious 
health problems [11, 17, 18].  The gold standard for treating periodontitis is using 
a regime of frequent professional cleanings, antibiotics to fight the bacterial 
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infection, and in severe cases, bone augmentation that usually requires multiple 
extensive surgical procedures to harvest autogenous donor tissue.   
To counter the onset of aggressive periodontitis and attempt to control or 
treat the infection, there are multiple steps that need to be considered. Some of 
these steps involve improved oral hygiene habits, removal of all bacterial plaque, 
and eventually treatment with regenerative medicine [8].  The goal of periodontal 
therapy is to rid the site of bacteria and reduce the inflammatory response by 
halting cytokines that are integral to the propagation of inflammation resulting in 
bone resorption, thus stopping the loss of bone and thereby preserving the 
natural dentition [10, 12].  Depending on the severity of the infection, there are 
many current but different options that are available.  Primarily dentists first rely 
on extensive debridement, such as scaling and root planning [9].  However, in a 
previous study described by Slots et al where nail polish was scaled from 
extracted teeth, it was shown that the investigator could not fully remove all 
plaque and bacteria adhered on a tooth’s surface [9].  This study demonstrates 
the unpredictable outcome of this basic procedure and exemplifies the need for 
further measures to fully fight periodontal bacterial infection.  Some of these 
other measures include the introduction of antibiotics, and even regenerative 
treatments using barrier membranes, autografts, demineralized freeze-dried 
bone allografts, bovine xenografts, and even combinations of membranes and 
fillers [11].  
 
2.3. Alveolar Bone Regeneration 
Currently the desire to create more biological alternatives to the 
permanent implantation of static synthetic materials for the management of 
periodontal defects has inspired the field of periodontal tissue engineering and 
regenerative medicine [8].  There is continuous research being performed to test 
existing regenerative technologies, both in human clinical trials as well as 
extensive animal studies to test modifications of existing devices.  Many human 
studies look at the effects of the disease itself using clinically approved 
technologies.  Martin et al. looked at and reported tooth loss during periodontal 
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treatment where patients were categorized at the inception of treatment by 
disease severity and risk level [12]. They concluded that categorizing a patient by 
severity may be beneficial in the management of the periodontal patient, and 
could give dentists guidelines for the proper treatment from a case by case basis 
[12].   
Augmentation procedures to allow for regeneration of alveolar bone are 
extensively tested trying to find the most suitable technology to use for one to 
make it easier to perform and ultimately beneficial for the patient’s well-being and 
recovery.  A human clinical study by Chiapasco et al. demonstrated how various 
augmentation procedures can all have similar outcomes [4].   In this particular 
study they looked at guided bone regeneration (GBR), onlay bone grafts, inlay 
grafts, bone splitting for ridge expansion, distraction osteogenesis, and 
revascularized flaps, all of which produced promising results; some slightly better 
than the other [4].  In another case study, the combination of natural bone 
mineral and guided tissue regeneration was investigated in eight patients with 
chronic advanced periodontitis displaying intrabony defects [19].  Windisch and 
his colleagues were able to conclude that the use of a guided tissue regenerative 
membrane covering a defect filled with natural bone mineral may be suitable for 
augmenting alveolar bone [19].  Again, many of these procedures require the use 
of donor tissue; whether it was retrieved from the host or alternative sites, there 
is still the requirement of a second surgery to harvest this tissue.  Since many 
alternative regeneration practices appear to have the same effect as donor 
tissue, the properties may even be further altered to allow for drug release and 
ultimately a much more rapid and healthy recovery.  The concept of this project 
investigates both of these scenarios.    
 
2.4. Current Approaches 
There are many different bone grafts and substitutes that could be used 
for bone augmentation.   Consideration in selecting a particular device includes 
characteristic capabilities, availability, patient morbidity, immunogenicity, 
potential disease transmission, and cost variability [20].  In addition the selected 
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bone graft would ideally be osteogenic, osteoinductive, osteoconductive, provide 
structural integrity, and have the ability to be osteointegrated to the host bone 
[20-22].  
 
2.4.1. Autografts 
Harvesting of autologous bone grafts from the patient tissue has been 
considered the ‘gold standard’ for augmentation procedures for alveolar ridge 
recovery [3, 20, 23, 24]. These bone grafts can be one of three different types; 
trabecular, corticotrabecular, or cortical [25]. Trabecular or cancellous bone 
tissue has been the most effective.  Autologous bone is composed of organic and 
inorganic structures [25].  The organic component, which is mostly comprised of 
collagen, provides resilience, toughness, and also continuity [25].  The inorganic 
portion contributes to the stiffness, hardness, and the rigidity [25].  This 
component is primarily a mineral known as hydroxyapatite (HA).  Within the 
inorganic mineral matrix osteocytes, osteoclasts, osteoblasts, and osteogenic 
signaling proteins and other mesenchymal tissues are found.  During 
transplantation very few of the mature osteoblasts within the graft survive, 
however, osteogenic potential remains due to a sufficient number of precursor 
cells [22]. 
Bone can be harvested from a number of locations, such as the iliac crest, 
ribs, or even from intraoral sites [20, 23].  For oral reconstruction, bone will 
usually be harvested from within the oral cavity.  Depending on the volume of 
bone needed for a given procedure, tissue can be removed from the maxillary 
tuberosity, ramus and symphysis on the mandible, or even debris from an 
implant osteotomy preparation. 
Along with the many benefits of using autologous bone, there are many 
disadvantages.  Because the tissue is taken from the patient a second surgery 
site is required, lengthening the overall surgical procedure.    Additionally, there is 
a limited volume of bone that can be harvested.  There are also many potential 
side effects when harvesting tissue.  Patients can experience donor site 
morbidity caused by a number of factors like blood loss, wound complications, 
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chronic pain, infection, local sensory loss, and may even lead to cosmetic defects 
[20, 24, 26]. 
 
2.4.2. Allografts 
 Recently, allografts have become the most frequently chosen substitute 
accounting for about a third of the bone grafts used in the United States, annually 
[3, 24].  Allograft tissue is harvested tissue taken from other individuals of the 
same species; often cadaveric bone.  This eliminates the need for a secondary 
surgical site which greatly reduces surgical time, blood loss, and amount of 
anesthesia required during the procedure [25].  It also leads to fewer 
complications like donor site morbidity in the patient.  By using cadaveric bone 
grafts, there is a much higher availability allowing for the tissues to be stored and 
distributed through tissue banks [24].  Allografts have the same characteristics as 
autografts, however they lack any osteogenic cells due to processing [22].  
These scaffolds come in three different forms; frozen, freeze-dried or lyophilized, 
and demineralized freeze-dried bone (DFDB).   Processing of the grafts once 
they have been harvested lowers the risk of disease transmission, such as 
hepatitis B & C, degenerative bone diseases, and STD’s [3].  In addition, 
processing of the tissue can greatly reduce the biological and mechanical 
properties which could lead to post-operative complications including fracturing, 
non-union of the graft, and although the risk has been reduced, host immune 
response [20, 22, 24]. 
 
2.4.3. Xenografts 
 Similar to allografts, xenografts are also tissues that are harvested from 
another source.  However, these particular grafts are obtained from different 
species [27].  Common tissue sources are bovine bone mineral and porous HA 
from coral skeletons [27].  BioOss® (Geistlich AG, Wolhusen, Switzerland) is 
considered one of the most commonly used bone graft substitute in dentistry [3].  
Upon processing to remove all organic material, what remains is a porous HA 
chip material having good mechanical properties and a structure similar to 
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human bone, however, shows very little solubility [3, 6, 28].  Coralline HA derived 
from marine coral has a highly porous and regular skeleton structurally 
resembling trabecular bone [20].  Most coralline HA is treated with ammonium 
phosphate and sterilized [20].  This process converts the calcium carbonate 
skeleton to crystalline HA which can be found as granule or block form [20].   
 
2.4.4. Alloplasts 
 Alloplastic bone grafts are becoming increasingly popular, however, no 
perfect substitute yet exists that possess the ideal qualities of an autograft [20].  
These types of bone grafts can be either synthetic or deorganified biocompatible 
materials having a verity of shapes, sizes, and/or textures [25].  Primarily 
ceramics, alloplasts can be either bioinert of bioactive [25].  Bioinert ceramic 
grafts comprise of aluminum oxides and titanium oxides.  These materials do not 
bond well to host tissue, therefore they are commonly used as endosteal 
implants, which can serve as oral abutments for dentures, or orthodontic 
appliances, and also used for bone fracture fixation [25].  Bioactive ceramics like 
hydroxyapatite (HA), tricalcium phosphate (TCP), and calcium sulfate (CS) are 
common bone substitutes [22, 25, 29].  Similar to bone, bioactive ceramics have 
been shown to have good compressive strength, however, alone they are brittle 
and have poor tensile strength [20, 25, 29].  When implanted, the ceramics 
undergo osteoconduction, although the biological response may differ from one 
implanted bone substitute to another due to differences in resorptive properties 
[25].    
 
2.4.4.1. Hydroxyapatite and Tri-Calcium Phosphates 
 Hydroxyapatite is the principal mineral component of bone and very 
osteoconductive and osteointegrative [20, 22, 25].  It has been used is posterior 
lumbar fusions, coatings on implants, and external fixator pins to assist in tissue-
implant interface [20].  HA has been shown to have a slow rate of resorption in 
vivo [20, 26].   
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Tri-Calcium Phosphate (TCP) is structurally similar to HA as well as the 
mineral phase of bone [20].  When implanted, TCP acts as a bioactive 
osteoconductive scaffold and integrates well with host tissue [20, 22].   Similar to 
HA and other phosphates, TCP has been shown to have good resistant to 
compressive loads, but brittle and weak under tension and shear [22, 30].  Both 
HA and TCP substitutes are available in paste, putty-like, solid matrix, or granule 
form [20].   
 
2.4.4.2. Calcium Sulfate 
Calcium sulfate (CS) has long been recognized as an osteoconductive 
and an osteointegrative biomaterial with an excellent reputation as a 
biocompatible substance [31-36]. In fact, it was one of the first bone substitutes 
used in orthopedics and dentistry [35]. It has been called upon for a variety of 
applications, such as long bone defects including osseous cavities related to 
tumors and cysts, and has been successfully used for craniofacial applications 
such as periodontal defects, alveolar bone loss recovery, and maxillary sinus 
augmentation [28, 37]. CS has similar mechanical strength to that of cancellous 
bone [38]. In vivo, CS is well tolerated, having the unique ability to become 
osteogenic in the presence of bone and completely absorbed by the host without 
inducing a significant inflammatory response [31, 33-35].  Characteristics of CS 
have been developed to closely match the rate of resorption by dissolution with 
the rate of new bone integration [36].  The rapid dissolution of CS leaves behind 
a calcium phosphate scaffold which helps promote osteogenic activity allowing 
for induce bone formation after two weeks in dogs and completely resorption 
after about one month [28, 39].   
 
2.4.5. Hybrid Bone Scaffolds 
 Hybrid scaffolds have been given much attention because these 3-
dimensional bone bioactive scaffolds can be fabricated from a variety of 
biomaterials such as bio-ceramics like the ones mentioned above and 
biodegradable polymers, natural or synthetic [40].  A number of synthetic and 
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natural polymers, as well as ceramics have been developed as bone tissue 
engineered biomaterials [1].  Because ceramics are very brittle and polymers 
have a weaker compressive modulus compared to native bone, combinations 
represent a promising alternative through the optimization of their physical and 
chemical properties to better mimic the tissue being replaced [40].  Many groups 
have developed different hybrid scaffolds; many of which have come with great 
success.  Cao et al. developed a polyglycolic acid and beta-tricalcium phosphate 
scaffold [41].  They were successful in showing the scaffold had degradation 
rates similar to the osteogenic rate and was completely replaced by new growing 
bone.  A hybrid system comprised of polycaprolactone and beta-tricalcium 
phosphate developed by Lu et al. demonstrated the tailorable physical properties 
of these types of scaffolds through mechanical stability throughout 
biodegradation [42].  In addition to the ability to produce composite formulations 
by utilizing advantageous properties of multiple materials, these biomaterials 
could be further enhanced by integrating biomolecules that would allow for the 
scaffold to be more osteoinductive [40]. 
 
2.5. Enhanced Bone Graft Substitutes: Bioactive Molecules 
Many groups are developing synthetic grafting substitutes to be suitable 
alternatives to the current standard use of autografts.  In doing so, several 
performance criteria must be met.  The synthetic bone graft substitute need to be 
biocompatible, osteoconductive, osteointegrative to help create a secure bond 
with the surrounding host tissue, and mechanically stable to ensure maintenance 
of surgical site being augmented.  Many currently used alloplasts, such as HA, 
TCP and CS, have demonstrated their ability to fulfill these criteria [41, 43, 44].   
However, for a synthetic material to be considered a suitable replacement for 
autografts, the grafting material also needs to be osteoinductive, and osteogenic.  
Synthetic bone graft substitutes may be further improved using bioactive agents 
like growth factors or other drugs capable of inducing new bone formation [45].  
Studies have shown enhancement of synthetic bone grafts through the release of 
bioactive molecules [45-47]. There are many growth factors that have been 
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studied for their potential use for bone regeneration.  Growth factors can act as 
mitogens in that they enhance proliferation of certain cell types [48].  In addition, 
some of these factors can be considered morphogenetic because of their ability 
to change the phenotype of their target cells [48].  First introduced by Dr. Marshal 
Urist in the 1960’s, bone morphogenetic proteins (BMP) have been extensively 
studied for their possibility of replacing the need for autografts with an 
engineered synthetic material capable of delivering these proteins [49].  The 
bone morphogenetic protein family consists of BMP-2 through BMP-8, which are 
dimeric molecules belonging to the transforming growth factor-β (TGFβ) 
supergene family [48-50].  The TGF-β family is named for its ability to transform 
fibroblastic cells in monolayer culture and to stimulate colony formation [14].   
BMPs are directly involved in the differentiation of cartilage and bone by 
controlling tissue induction and morphogenesis [49-51].  The most effective 
BMPs in terms of osteogenesis are BMP-2, BMP-4, and BMP-7 [48].  Introducing 
growth factors into grafting devices can induce rapid new bone formation, 
allowing for a reduction in healing time to achieve sufficient new bone volume for 
proper anchoring of an inserted implant [47, 52].  Other growth factors have been 
commonly considered due to their influence in skeletal regeneration and 
maintenance [48].  Insulin-like growth factor (IGF) plays an important role in 
general growth and maintenance of the skeleton, and has long been considered 
a circulating mediator of growth hormone (GH) [48].   There are two different 
isoforms, IGF-1 and IGF-2.  IGF-1 has been known to be exclusively used in 
reconstructive surgery [48]. Vascular endothelial growth factor (VEGF) is another 
increasingly important growth factor and is considered one of the key regulators 
of angiogenesis during bone formation [53, 54].  Not only is the induction of new 
bone important, but equally important is the regeneration of the vasculature to 
allow for a fresh supply of nutrients to the site of tissue regeneration.  Kempen et 
al. demonstrated the sequential release of VEGF along with BMP-2 promoted a 
significant increase in ectopic bone formation compared to BMP-2 alone [54]. 
A promising alternative to the use of growth factors is the use of smaller 
molecule drugs such as statins.  Statins are commonly known as an inhibitor of 
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3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase and often 
prescribed to control cholesterol levels [55, 56].  Statins have been extensively 
studied for their ability to stimulate bone regeneration [57-60].  There are many 
statins that have demonstrated their ability to stimulate bone growth (i.e. 
simvastatin, lovastatin, fluvastatin).  Simvastatin promotes bone formation in vitro 
and in vivo through the stimulation of osteoblastic activity and inhibition of 
osteoclastic activity [55, 56].  The successful use of simvastatin in vivo is largely 
controlled by the local concentration of the drug [55].  Houshmand et al. 
demonstrated simvastatin and lovastatin ability to promote ectopic bone 
formation following subcutaneous injections along or near bone [57].  However, 
due to its pharmacokinetic characteristics of being poorly absorbed and actively 
cleared in the liver, controlling the local release of relatively higher amounts of 
simvastatin to maintain a therapeutic level of drug suitable for accelerated bone 
regeneration would be ideal [56]. 
 
2.6. Drug Delivery of Bioactive Agents 
Being able to control the delivery of drugs to a bony defect allows for 
tunable dosing, as well as for extended retention time of agents being delivered 
[61].  However, an ongoing question relates to how bioactive molecules can be 
delivered to maximize their therapeutic potential [62].  A common trend to help 
address this issue is the use of biodegradable carrier substances incorporated 
into existing grafting devices or even directly incorporating the agents into 
scaffolds.  Biodegradable polymers have been used as biomaterials in controlled-
release applications [62-66].  Many of these that have been investigated for the 
delivery of osteoinductive factors including collagen networks, gelatin, poly(lactic 
acid) (PLA), polyanhydrides, and poly(DL-lactide-co-glycolide) (PLGA) [62].  
PLGA is a biocompatible and biodegradable polymer that is a copolymer of poly 
lactic acid (PLA) and poly glycolic acid (PGA) [67, 68].  They are very popular 
among biodegradable polymers because of their long clinical history, favorable 
degradation characteristics which can be tuned by adjusting the polymer 
molecular weight and ratio of lactide to glycolide, and for its use as a drug 
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delivery apparatus for bioactive agents [68].  PLGA undergoes degradation by 
hydrolysis or biodegradation through cleavIsobe et al. developed and tested a 
PLGA capsule containing BMP [69].  Their controlled release system was shown 
to have gone through complete digestion followed by newly regenerated bone 
after 3 weeks [69].  PLGA has also been shown to be a good drug delivery 
vehicle in the form of microspheres embedded into a ceramic matrix.  Yang et al. 
developed tri-calcium phosphate composites containing PLGA microspheres for 
the delivery of dexamethasone and bovine serum albumin [70].  The intended 
use of this device was to work not just as a scaffold, but also capable of 
controlled local delivery of drugs or bioactive agents to accelerate bone 
regeneration at the defect site [70].   
Hydrogels provide specific advantages for the delivery of growth factors 
due to their high water content, biocompatibility, and controlled degradation [62].  
There are many promising hydrogels that are capable of delivering bioactive 
agents [62, 65, 71].  Gelatin have been used widely in preparation of enzyme-
degradable protein hydrogels [65].  It is a natural polymer derived from collagen 
(Young).  These gels are commonly used for pharmaceutical and medical 
applications because of the biodegradability and biocompatibility (Young).  A 
controlled release platform using BMP-2 loaded gelatin hydrogel developed by 
Sawada’s group demonstrated significant bone regeneration [72].  The gel was 
capable of controlling the delivery of protein resulting in a greater volume of bone 
formation compared to their controls (Swada).  Poly(ethylene glycol) (PEG) 
hydrogels have also been shown to be beneficial as a material for tissue 
regeneration whether it be used as a drug delivery apparatus or a scaffold for 
osteoblasts [62, 73].  A unique family of biodegradable hydrogels, poly(β-amino 
esters) (PBAE), developed by Anderson et al  has also been proposed for use in 
tissue regenerative applications [74, 75]. These gels can have a wide range of 
physical/chemical properties based on their macromer formulations [66, 74].  
Several groups have investigated PBAE’s potential as carrier materials for 
controlled delivery of bioactive agents [66, 76-80]. 
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2.7. Significance 
The purpose of the work described in this document was to demonstrate 
how a rather simple material, calcium sulfate, with a strong successful history as 
a synthetic bone graft substitute could be further enhanced to become a suitable 
alternative to the ‘gold standard’ autograft.  By allowing the material to be tailored 
into a customizable composite capable of controlling the local administration of 
bioactive agents, this device could be developed and tuned with the patient’s 
needs in mind based off of the prognosis of the surgical site.  The outcome will 
not only eliminate the need for either multiple grafts, membranes, or surgeries, 
but will allow for the process to be as minimally invasive as possible allowing 
faster patient recovery and greatly having an effect on their overall health and 
well-being.  Described below are the different specific aims that were achieved in 
the development of these calcium sulfate based bone graft substitutes. 
 
2.8. Specific Aims 
Specific Aim #1: Development and characterization of a calcium sulfate 
based space making composite bone graft substitute capable of controlled 
release of bioactive agents. 
Calcium sulfate hemihydrate based composites embedded with poly(β-
amino ester) (PBAE) biodegradable hydrogel particles were developed to act as 
a ‘tenting’ barrier to soft tissue infiltration, theoretically providing adequate space 
to enable vertical bone regeneration. Composite samples were fabricated with 
varying amounts (1 or 10 wt%) and sizes (53-150 or 150-250 µm) of gel particles 
embedded in CS. The swelling and rate of degradation of PBAE gels was 
explored; an important characteristic to aid in controlled release of drug.  Micro-
computed tomography (MicroCT) imaging was done to monitor particle 
distribution within the CS matrix.  Destructive dissolution studies of composites 
was conducted to demonstrate the length of time it took for CS to complete 
dissolve as well as monitor how gel particles (1 wt% and 10 wt%) would influence 
the rate of dissolution.  Compression testing was done to characterize the 
mechanical properties of CS composites with embedded gel particles.  A pilot 
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release with curcumin loaded PBAE gels embedded in a CS matrix was 
performed to demonstrate the potential for drug release from CS-based 
composites. 
 
Specific Aim #2: Demonstrate the capability of controlled release of a broad 
range of bioactive agents from CS-based composites.  
CS composites developed in specific aim #1 were investigated for their 
drug delivery potential of a broad range of bioactive agents.  Samples were 
produced with either directly loaded small, hydrophobic molecule (i.e., 
simvastatin), directly loaded hydrophilic protein (i.e., lysozyme), or 1 and 10 wt% 
of H6 poly(β-amino ester) (PBAE) particles containing protein.  The release 
kinetics of the composites was evaluated for the sustained release of two very 
different drugs.  Compression testing was also performed to monitor how the 
loading of drug directly into the CS matrix would affect the mechanical stability of 
the composites.   
 
Specific Aim #3: Development of a bilayered composite with tailorable 
geometries and demonstrated sequential release   and multiple hydrogel 
loaded space making calcium sulfate/hydrogel composite for tailored drug 
delivery of simvastatin and metronidazole to treat chronic periodontal 
disease. 
Tailorable bilayered calcium sulfate (CS) bone graft substitutes were 
developed with the ability to sequentially release multiple therapeutic agents.  
Bilayered composite samples having a shell and core geometry were fabricated 
with varying amounts (1 or 10 wt%) of metronidazole-loaded poly poly(lactic-co-
glycolic acid) (PLGA) particles embedded in the shell and simvastatin directly 
loaded into either the shell, core, or both.  Microcomputed tomography (MicroCT) 
imaging was conducted to showed the overall layered geometry as well as 
determine the homogeneity of particle distribution within the shell.  A destructive 
dissolution studies were performed to demonstrate the effect of PLGA particles 
(i.e., 1 vs. 10 wt%) may have on the composite during degradation.  
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Compressive mechanical testing was conducted to determine how the 
introduction of a layered geometry would influence the mechanical properties of 
the composite.  Release studies of simvastatin directly loaded into the layers of 
CS were studied.  By introducing a tunable layered geometry the release kinetics 
of simvastatin was monitored.  A multiple drug release study was conducted to 
investigate the sequential release capacity of CS composites with metronidazole 
loaded PLGA particles embedded in the shell and simvastatin directly loaded into 
the CS matrix (either in shell, core, or both layers). 
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Chapter 3:  Effect of Macromer Synthesis Time on the Properties of the 
Resulting Poly(β-amino ester) Biodegradable Hydrogels 
 
3.1. Introduction 
Dental implants have become a preferred method for replacing teeth lost 
to trauma or disease. Unfortunately, the disease processes which result in tooth 
loss may also cause the loss of supporting bone [81]. Implant placement requires 
sufficient bone to allow a proper anchor [81, 82]. Thus, bone regeneration or 
augmentation is often required prior to or concomitant with implant placement 
[81, 82]. Guided bone regeneration (GBR) is a common technique in which a 
barrier membrane is used to create a protected ‘healing chamber’ where bone 
growth may occur. The barrier helps stabilize the blood clot and graft material 
and helps exclude the ingrowth of epithelium or fibrous connective tissue, either 
of which may interfere with the more slowly growing immature bone tissue [83]. 
These membranes may be either resorbable (e.g., collagen) or non-resorbable 
(e.g., expanded polytetrafluoroethylene). The latter requiring a second stage 
surgery to remove the membrane. 
GBR membranes are often used in conjunction with an autogenous bone 
graft because of their tendency to collapse and subsequent inability to create the 
growth space by themselves [84, 85]. Although autogenous bone has been 
widely accepted as the gold standard augmentation material, its availability from 
intra-oral donor sites is limited [82, 86, 87]. In the oral cavity, donor tissue is often 
harvested from the ramus or the symphysis of the mandible, and this can lead to 
undesirable donor site morbidity [31, 37, 84, 88-96]. A biologically compatible 
synthetic bone grafting substitute that is osteogenic, biodegradable/bioerodible, 
and provides spacing-making functionality could help eliminate the need for 
harvested bone or GBR membranes in the future. 
Researchers have investigated many biocompatible ceramic materials as 
scaffolds for bone regeneration in attempts to replace the gold standard use of 
autogenous bone grafts. Calcium phosphates, such as hydroxyapatite and 
tricalcium phosphate, have been given much attention because of their likeness 
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to natural bone mineral [37, 93, 97-100]. Calcium sulfate (CS) hemihydrate has 
long been recognized as an osteoconductive biomaterial with an excellent 
reputation as a biocompatible substance [31-35]. In fact, it was one of the first 
bone substitutes used in orthopedics and dentistry [35]. It has been called upon 
for a variety of applications, such as craniofacial and long bone defects, as well 
as osseous cavities related to tumors and cysts [37]. Characteristically, CS has 
similar mechanical strength to that of cancellous bone [38]. In vivo, CS is well 
tolerated, having the unique ability to become osteogenic in the presence of bone 
and completely absorbed by the host without inducing a significant inflammatory 
response [31, 33-35]. 
In this study, calcium sulfate-based composites embedded with poly(β-
amino ester) biodegradable hydrogel particles were developed to act as a 
‘tenting’ barrier to soft tissue infiltration, thereby potentially enabling vertical bone 
regeneration ultimately leading to a suitable depth of bone for implantation of a 
prosthesis. The photocrosslinked biodegradable gel particles presented in this 
study are part of a family of materials initially developed by Anderson et al [74, 
75]. These gels can have a wide range of physical/chemical properties based on 
their macromer formulations [74]. For the purpose of the composite system 
presented, a gel with a rapid degradation rate was selected as the filler that 
potentially may also serve as a delivery vehicle for pharmaceuticals. The 
introduction of these biodegradable gel particles into the composite matrix could 
improve the osteogenic properties of CS through a tailored, controlled release of 
bioactive molecules. Being able to control the delivery of drugs to a bony defect 
allows for tunable dosing, as well as for extended retention time of drugs being 
delivered [61]. For the present study, composites were embedded with unloaded 
poly(β-amino ester) biodegradable hydrogel particles. Their influence on the rest 
of the CS composites’ physical and chemical characteristics, namely mechanical 
strength and modulus, dissolution, and morphology, were studied. In addition, a 
pilot release study was conducted to demonstrate the release controllability of 
curcumin-loaded poly(β-amino ester) particles embedded in a CS matrix. 
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3.2. Materials & Methods 
3.2.1. PBAE gel synthesis 
A11 poly(β-amino ester) (PBAE) macromer was synthesized according to 
previously described methods [74, 75]. To review, step-growth polymerization 
was performed by combining a 1.4:1 molar ratio of diethylene glycol diacrylate 
(2.079 g; Polyscience, Inc., Warrington, PA) and 3-morpholinopropyl amine (1.0 
g; Sigma Aldrich, St. Louis, MO). The reaction took place in a flask partially 
submerged in a silicon oil bath pre-heated to 85°C on a heated stir plate. After 
continuously stirring the reaction mixture for 16 h, it was removed from the heat 
and stored at 4°C until used.  
Biodegradable hydrogels (HG) were subsequently made using a photo-
initiated polymerization process. Two grams of cooled macromer were combined 
with 1 wt% of 2,2-dimethoxy-2-phenyl-acetophenone (DMPA; Sigma Aldrich, St. 
Louis, MO) initiator and dissolved in 1.25mL of dimethyl sulfoxide (DMSO). After 
vortexing for 60 sec, the homogeneous mixture was sandwiched between two 
glass plates using a 1.5 mm Teflon spacer to contain the viscous fluid. The 
macromer was exposed to UV radiation using a Lesco UV flood source (14 
mW/cm2) for 5 min to initiate and propagate the photo-polymerization process. 
After polymerization, the gel was removed from the glass, washed for 30 min in 
ethanol to remove any unreacted initiator and macromer, and then freeze dried.  
 
3.2.2. PBAE gel Swelling and Degradation 
Swelling was measured as reported by Hawkins et al. [101]. Square (1 
cm2) HG samples were submerged in deionized (DI) water or PBS and kept at 
37°C. For the first hour, samples were removed from the fluid, carefully dabbed 
dry, weighed, and placed back into fluid every 10 min. During the second and 
third hours, samples were removed and weighed in the same fashion every 20 
min. After three hours, the time intervals were increased to every hour until the 
sample could no longer be handled or the samples were completely degraded. 
The extent of swelling [S%] was determined using equation 1,  
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[Eq. 1] 
 
where Mt was the mass at a particular time point and Mo was the initial mass. 
 
3.2.3. Composite Formation 
The composites consisted of calcium sulfate hemihydrate (CS; Sigma 
Aldrich, St. Louis, MO) as the structural matrix and varying amounts of A11 HG 
particles. Gel particles were hand-ground from polymerized gel slabs. In order to 
coat the gel particles and prevent them from sticking to one another, as well as to 
allow grinding to be efficient, small amounts of CS powder were added during 
grinding. Particle sizes of 53-150 μm and 150-250 μm were obtained from 
grinding and sieving. To make CS control samples, 1 g of CS powder was mixed 
with 800 µL of deionized (DI) water for about 30 sec or until thoroughly mixed in 3 
ml non-sterile syringes. The slurry was loaded into a custom-fabricated Delrin 
mold that could yield up to 46 samples with an average diameter of 4.75 mm and 
a height of about 6.5 mm. The mold was placed in a 43°C oven for 24 h to set the 
CS. For 1 wt% HG composite samples, 0.01 g HG was mixed with 0.99 g CS and 
850 µL DI water. Samples with 10 wt% HG consisted of 0.1 g HG, 0.9 g CS, and 
900 µL DI water. As with the controls, the composite mixtures were loaded into 
the mold and left to set in a 43°C oven for 24 h.  
 
3.2.4. PBAE Particles and Composite Microarchitecture 
3.2.4.1. PBAE Microarchitecture  
Using an Olympus IX51 light microscope, a small amount of PBAE gel 
particles from each size fraction, 53-150 and 150-250μm, were placed on glass 
slides and visually assessed. The physical structure of the particles was 
investigated to develop a qualitative understanding of their size distribution for a 
particular sieved fraction, as well as their appearance when embedded in a CS 
matrix. In addition to qualitative observations, the particle size was quantified 
using ImageJ.  
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3.2.4.2. Composite Microarchitecture 
To monitor the distribution of HG particles within the CS matrix, 
microcomputed tomography (microCT) was used. Using a Scanco Medical μCT-
40 scanner, specimens were evaluated with standard resolution having 250 
projections with 1024 samples each. Additional parameters were set as follows: 
92 μm increments, 0° angle, 70 kVp, 114 μA, 0.5 mm Al filter, and a voxel size of 
12 μm. The resulting microarchitectural images were qualitatively investigated for 
any particle distribution trends. To qualitatively and quantitatively assess the 
composites, samples were evaluated with a lower threshold level of 109 before 
running a built-in ‘bone trabecular morphometry’ analytical tool. This tool created 
a three dimensional reconstruction that allowed assessment of the composite 
structure and its embedded gel particles as well as provided the volume 
percentage of embedded gel particles, average particle size, and average 
spacing between particles.  
 
3.2.5. Composite Degradation 
Destructive mass loss testing was performed to monitor degradation of the 
various composites. Samples of each type (control, 1 wt% HG, and 10 wt% HG) 
were weighed, measured (height and diameter), placed in separate plastic vials 
containing 4 mL of phosphate-buffered saline (PBS), pH 7.4, and incubated on a 
plate shaker at 37ºC. Every four days, samples were removed and dried in a 
43ºC oven for a minimum of 24 hr. For the remaining samples, the PBS in vials 
was replaced with fresh PBS. The dried samples were weighed to determine the 
amount of mass lost. 
3.2.5.1. Degradation: Changes in Fluid Volume 
Mass loss using different fluid volumes was tested to determine the effects 
on composite dissolution rates. The experimental method for mass loss 
described above was used. Five different fluid volumes were tested: 0.5, 1.5, 3, 
4, and 6 mL. 
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3.2.6. Composite Mechanical Testing 
Compression testing was performed using a Bose ELF 3300 system. 
Samples without any noticeable external defects, such as cracks and/or voids, 
were chosen for testing. Contact surfaces were lightly sanded, if necessary, 
using 600 grit SiC paper to provide smooth, parallel surfaces in contact with the 
compression platens. Control, 1 wt% HG, and 10 wt% HG samples were tested 
at a rate of 0.5 N/sec until failure. Compressive modulus (M) and ultimate 
compressive strength (UCS) were calculated. 
 
3.2.7. Pilot Release Study with Curcumin 
 A pilot study of drug release from the composite was performed to 
demonstrate the potential for controlled release from drug loaded PBAE gel 
particles embedded in a CS matrix. PBAE gels were produced with 50 wt% 
curcumin using a method previous described [102]. The finished gels were 
washed in 5 mL of acetonitrile for 1 hr. This was repeated 4 times after which the 
gels were lyophilized overnight. Gels were hand ground with small amounts of 
CS as a drying agent and sieved to obtain particles ranging from 53-150 μm or 
150-250 μm. Drug loaded particles were washed with DI water for 1 minute to 
remove CS. The washed particles were filtered and lyophilized once more. 
Composites were produced using the same steps described above for both 1 
wt% HG and 10 wt% HG composite formation. 
 Completed samples were weighed, submerged in 4 mL of PBS, and 
placed on a shaker plate in a 37°C oven. To allow for sink conditions, every 4 
days the supernatant was collected and fresh PBS was added. This continued 
until all samples completely degraded. For each measurement, 1 mL of collected 
supernatant was treated with 50% ethanol to dissolve any suspended drug and 
filtered using 0.45 μm syringe filters. Supernatant from the 10 wt% HG samples 
was diluted to allow for accurate measurement. Gel washings and treated 
supernatant were measured with UV/Vis spectrophotometry at an absorbance of 
420 nm.  
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3.2.8. Statistics 
Statistical analysis of the results was performed using either a two-tailed 
unpaired t-test or two-way ANOVA. As appropriate, this was followed up with a 
Tukey-Kramer multiple comparisons post hoc test. Differences between groups 
were considered to be significant with p-values <0.05. 
 
3.3. Results 
3.3.1. PBAE gel Swelling and Degradation 
The degree of hydrogel swelling and degradation based on the mass of 
liquid absorbed by the samples is displayed in Figure 3.1. During the first 60-80 
minutes, the gels swelled quickly, but the rate gradually slowed and reached a 
plateau around 160 minutes. After this initial stage, the full extent of swelling 
appeared to reach a maximum for gels submerged in PBS, and the samples did 
not show any significant signs of further swelling. After 300 minutes, the gels 
submerged in DI water began to absorb liquid again at a significantly higher rate 
(p<0.0001) and continued until the end of the experiment. The study was 
concluded around 420 minutes when the samples became fragile and difficult to 
handle. 
 
3.3.2. Composite Morphology 
3.3.2.1. Qualitative Evaluation 
Under a light microscope, gel particles were seen as large, irregularly 
shaped objects along with some dispersed prism-like particles considered to be 
residual calcium sulfate (Figure 3.2). Quantitative analysis demonstrated that the 
size distribution of gel particles was within the expected limits, 53-150 μm and 
150-250 μm (data not shown).  
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Figure 3.1. Swelling of A11 PBAE gels in diH2O and PBS. Data are mean ± 
standard deviation (n=6).  
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A.  
B.  
Figure 3.2. Morphology of A11(1.4) PBAE gel particles: A) 150-250 μm and B) 
53-150 μm sieved size fractions. Irregularly shaped objects are gel particles 
(solid white arrows), and small particles are residual calcium sulfate (open white 
arrows). 
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MicroCT analysis showed the size and distribution of gel particles 
embedded in CS (Figure 3.3). In samples with 10 wt% loading of particles, there 
was a uniform distribution of particles throughout the CS matrix (Figures 3.3D, 
E). In Figures 3.3B and 3.3C showing composites with 1 wt% loading of gel 
particles, although the distribution was sparser, the particles still appeared to 
have been uniformly distributed throughout the matrix. Although all composite 
loadings showed a good distribution of particles, none of the samples were 
without some minor defects. For example, all samples had a few air pocket 
defects (black arrows in Figure 3.3) embedded along with gel particles. These 
defects were nearly spherical in nature and thus easily distinguishable from gel 
particles, which had irregular shapes as previously shown in Figure 3.2.  
3.3.2.2. Quantitative Evaluation  
 Quantitative analysis was performed to develop a greater understanding 
of the physical structure of the composites than could be achieved by a 
qualitative analysis alone. Figure 3.4 shows the average porosity, average 
spacing between particles/voids, and average particle/void size for the different 
composite compositions. The porosity of about 8.31% for 10 wt% HG (150-250 
μm) loading was significantly different (p<0.001) from all other loadings tested 
(Figure 3.4A). For all other configurations there were no significant differences in 
porosity among them.  
 For the average spacing between particles/voids, the blank samples were 
significantly different (p<0.001) compared to 1 wt% HG (53-150 μm), 10 wt% HG 
(53-150 μm), and 10 wt% HG (150-250 μm) samples (Figure 3.4B). Differences 
in void spacing between the 1 wt% HG loadings for both particles sizes proved to 
be significantly different [p<0.01, 1 wt% HG (53-150μm) vs. 1 wt% HG (150-
250μm)]. When comparing the different loadings for a particular particle size, the 
distance between particles for the 1 wt% HG loadings were significantly larger 
(p<0.001) compared to the 10 wt% HG loadings except for the 1 wt% HG (53-
150μm) vs. 10 wt% HG (53-150μm) relationship which was significantly different 
with a p<0.05.  
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 The average particle and/or void size (Figure 3.4C) demonstrated 
significant differences for 1 wt% HG (53-150 μm) versus both 10 wt% HG (53-
150 μm) (p<0.001) and 10 wt% HG (150-250 μm) (p<0.05). 
 
3.3.3. Composite Degradation 
During the mass loss experiments, all sample groups were tested 
simultaneously. Loading 1 wt% of gel particles did not have a significant effect on 
the dissolution rate (-3.71%/day) of the overall composite (Figure 3.5). However, 
increasing the gel loading to 10 wt% did significantly increase the dissolution rate 
-4.42%/day (p<0.05), even though complete dissolution varied by only about four 
days. 
3.3.3.1. Degradation: Changes in Fluid Volume 
 Similar to the composite degradation experiment, all sample types were 
tested using the same PBS solution to avoid fluid dependent effects on 
dissolution except volume change. Shown in Figure 3.6, small fluid volumes of 
0.5 or 1.5 mL proved to cause significantly slower dissolution, -0.6 or -2.7%/day, 
respectively (p<0.001). Increasing the fluid volumes to 3, 4, or 6 mL contributed 
to dissolution rates of -5.1, -6, or -6.6%/day, respectively. When compared to 3 
mL, fluid volumes of 4 mL and 6 mL had significantly faster dissolution rates 
(p<0.05 and p<0.001, respectively).  
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Figure 3.3. MicroCT images of calcium sulfate/gel composites: A) Blank CS and 
B) 1 wt% HG 53-150 μm, C) 1 wt% HG 150-250 μm, D) 10 wt% HG 53-150 μm, 
E) 10 wt% HG 150-250 μm. Air pockets indicated by black arrows. All scale bars 
are 1.0 mm. 
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A.  
B.  
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C.  
Figure 3.4. Quantitative morphometric results from microCT: A) Average 
porosity, B) Average spacing between particles for blank and composite CS 
samples, and C) Average size of particles/voids within CS matrix. Data are mean 
± standard deviation (n=5). Symbols indicate significant differences: p<0.001 (*), 
p<0.001 (**), p<0.01 (#), and p<0.05 (Δ).  
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 Figure 3.5. Dissolution profiles for blank calcium sulfate, 1 wt% HG), and 10 wt% 
HG composites. Data are mean ± standard deviation (n=3).  
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Figure 3.6. Dissolution profiles for blank calcium sulfate submerged in different 
volumes of PBS. Data are mean ± standard deviation (n=3).  
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3.3.4. Composite Mechanical Testing 
Effects of HG loading on the compressive mechanical properties are 
shown in Figure 3.7. The ultimate stress for control blank CS samples were 
significantly greater than both 10 wt% HG loadings with a p<0.0001 and 1 wt% 
HG loadings (p<0.001). Blank CS elastic modulus, however, was only 
significantly greater than the 10 wt% HG loadings (p<0.0001). Composite 
samples with 1 wt% HG had 80-90% of the strength compared to the controls. 
The 1 wt% addition of gel particles had no significant effect on the modulus when 
compared to blank samples. Adding 10 wt% HG resulted in about 40-50% of the 
stress and 25-30% of the modulus of particle-free samples. Comparing samples 
loaded with 1 wt% HG of either 53-150 μm or 150-250 μm particles showed a 
significant difference (p<0.01) in their strength (3.99 ± 1.19 MPa versus 4.89 ± 
0.38 MPa, respectively), however, there was no significant difference in the 
elastic modulus (401.35 ± 156.92 MPa and 369.1 ± 224.58 MPa, respectively). 
The strength of 10 wt% HG for both particle sizes were also significantly different 
with a p<0.01 [2.57 ± 0.24 MPa (53-150 μm) and 1.94 ± 0.36 MPa (150-250 
μm)], but there wasn’t any significant difference between their elastic moduli. 
Comparing the two different particle sizes and their different weight percentages 
there were significant differences as well. For either particle size, the ultimate 
strength of composites containing 1 wt% HG particles was significantly greater 
than that for 10 wt% HG loadings [p<0.05 for 1 wt% HG( 53-150μm) vs. 10 wt% 
HG (53-150μm), and p<0.0001 for all other composite comparisons]. The elastic 
modulus of 1 wt% HG (53-150 μm) vs. both 10 wt% HG loadings was 
significantly different with a p<0.001, whereas the differences in the elastic 
modulus of 1 wt% HG (150-250 μm) vs. both 10 wt% HG loadings was a little 
less significant with a p<0.01. 
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A.  
B.  
Figure 3.7. Mechanical properties of CS-HG composites: A) Ultimate 
compressive strength and B) compressive modulus of blank and composite 
calcium sulfate samples. Data are mean ± standard deviation (n=10). Symbols 
indicate significant differences: p<0.0001 (*), p<0.001 (**), p<0.01 (#), and 
p<0.05(Δ). 
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3.3.5. Curcumin Pilot Release 
 Figure 3.8 illustrates the pilot release kinetics of CS composites 
embedded with PBAE particles loaded with curcumin. For both 1 wt% HG 
loadings, the release of curcumin was steady where about 30% was released 
after the first 4 days and only 60-70% of the drug released during the first half (14 
days) of the study. Over the course of the study there was a slow decay of the 
daily release percentage from the 1 wt% HG composites; 8%/day at 4 days, 
6%/day at 10 days, and 4%/day at 20 days. Conversely, 10 wt% HG loadings 
started with a larger burst (50-60%) release of drug over the first 4 days followed 
by nearly 90% of the loaded drug released during the first 14 days of the 28 day 
study.  
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A.  
B.  
Figure 3.8. Release profiles for 1 wt% HG (53-150 μm and 150-250 μm) and 10 
wt% HG (53-150 μm and 150-250 μm) composites. Data are mean ± standard 
deviation (n=5). 
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3.4. Discussion 
The aim of this study was to understand the physical and chemical 
characteristics of a composite bone graft substitute that has the potential to act 
as a ‘tenting’ barrier to soft tissue infiltration for creating a chamber for bone 
regeneration, while simultaneously allowing for the controlled release of bioactive 
agents. The regenerated bone could provide a sufficient platform for stable 
placement of dental implants in periodontal applications. 
 
3.4.1. PBAE gel Swelling and Degradation 
Degradable PBAE gel particles were synthesized to serve as a protective 
delivery vehicle for osteogenic agents and/or other drug(s) when embedded in a 
calcium sulfate matrix. Initial studies were performed to determine whether 
swelling of the particles following exposure to a physiological environment would 
be extensive enough to adversely affect the overall composite structure. In vitro 
experiments showed three distinct stages in the swelling profiles. After the initial 
swelling stage, absorption of liquid slowed, eventually reaching a plateau. It has 
been well established that swelling of hydrogel occurs due to the electrostatic 
repulsion of ionic charges within the polymer due to the presence of absorbing 
liquid [103, 104]. During the plateau phase, osmotic forces driving fluid into the 
hydrophilic gels equaled the opposing elastic force created by the stretching of 
the crosslinked polymer. After the plateau, the polymer backbone began failing at 
a faster rate through hydrolytic scission of the ester bonds, yielding small 
molecule bis(β-amino acids), diol products, and poly(acrylic acid) kinetic chains 
[74]. This gradual breakdown of the polymer matrix allowed for further expansion 
of the mesh and continued absorption of liquid into the gel. Anderson et al. had 
previously demonstrated that A11 PBAE gels degrade very rapidly (<24 hr), 
which is similar to the results seen in the present study where gels began to 
rapidly breakdown through hydrolysis beginning around 4-5hr resulting in 
complete degradation in less than 24 hr [74].  
 An advantage with the PBAE family of hydrogels is that there are a variety 
of possible combinations of diacrylates and amines that can produce similar 
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range of properties. Hawkins et al. studied a PBAE gel comprising poly(ethylene 
glycol) diacrylate (H) and isobutylamine (6) in a 1.2 molar ratio [101]. The 
components are different from those used for the present A11 gel, however, the 
H6 system studied by Hawkins also degraded in less than 24 hours.  Although 
the H6 gel swelled about 50% more during the first 4hr compared to the A11 
gels, they both reached a plateau followed by a rapid degradation of the polymer 
starting around 4-5hr [101]. The similarities between these two PBAE’s 
demonstrate the versatility of this gel family and how the gel component in this 
system may be altered to accommodate different formulations if needed.   
 
3.4.2. Composite Morphology 
When creating the gel particles to be embedded in calcium sulfate, gel 
slabs were ground with a small amount of calcium sulfate to act as a ‘drying 
agent’ similar to talcum powder to prevent particles from sticking to one another. 
Images showed a small amount of calcium sulfate crystals remaining with the gel 
particles after sieving. The smaller 53-150 μm gel particles had more residual 
calcium sulfate compared to the larger 150-250 μm particles. Calcium sulfate is 
inherently denser than the gels. Therefore, the greater amount of calcium sulfate 
present with the 53-150 μm size particles must be taken into account in future 
studies investigating drug loading and release. The larger particles have a 
smaller surface area to volume ratio compared to the smaller particles, thus 
requiring a smaller amount of calcium sulfate to coat and process the particles.  
Qualitative analysis of microCT images indicated a uniform distribution of 
gel particles at both 1 and 10 wt% loadings. The composite slurry, when mixed 
well, allows for a short working window for easy filling of the molds because of 
the rapidly setting nature of the calcium sulfate. Due to the viscosity of this slurry, 
gel particles were suspended and prevented from aggregating with one another. 
Also, any buoyancy effects that could cause particles to collect at one end of the 
samples and cause inhomogeneity were prevented. Once set, the gel particles 
were locked in place, and any swelling of particles that may have occurred while 
mixing the slurry was reversed resulting in contraction of these particles.  This in 
39 
 
turn creates protective voids wherein dried gel particles reside. An important 
feature of this process was the creation of a tolerance ‘gap’ between the wall of 
the voids and the HG particles preventing composite failure due to swelling of gel 
particles during CS dissolution. In addition, because these irregularly shaped 
voids are stress concentrators themselves, they may also affect structural 
integrity under an applied load.  
 Quantitative evaluation of the composites’ porosities showed a dramatic 
decrease in porosity for the 10 wt% HG loading of 53-150 μm particles (2.67%) 
compared to the 10 wt% HG of 150-250 μm particles (8.31%). The presence of 
residual calcium sulfate, especially with the 53-150 μm size fraction, could affect 
loading because the CS will incorporate with the rest of the matrix, leaving 
behind a smaller quantity of gel particles. Interestingly, residual calcium sulfate 
did not play a significant role when comparing the 1 wt% HG loadings for both 
particle sizes. The contribution of air pockets to the porosity, particle/void spacing 
and size calculations for 1 wt% HG specimens may have counteracted the 
effects of residual CS described above. However, the number of possible air 
pockets within the 10 wt% HG loadings may not have significantly contributed to 
these calculations due to the much larger quantity of gel particles present. This 
trend can be exemplified using the particle size measurements for 1 wt% HG (53-
150 μm) and 10 wt% HG (53-150 μm) where the resulting porosity values were 
significantly different, although the particles used for these composites were the 
same. 
 
3.4.3. Composite Degradation 
CS composites degrade by means of dissolution and subsequent surface 
erosion. Bulk degradation was not observed because of the dense nature of the 
ceramic and lack of an open-celled porous network. Although the gel particles 
created a porous structure within the matrix, the pores were ‘closed’. This 
structure should enable the composites to achieve zero-order release, whereby 
only the gel particles exposed on the surface during CS erosion will be permitted 
to swell, degrade, and release their active molecules. The HG loading-
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independence of composite degradation rate may allow for easy tuning to 
provide long enough mechanical stability or protection from soft tissue infiltration 
while also allowing the sustained delivery of a sufficient amount of drug-loaded 
HG particles to stimulate bone formation. 
Lewis et al. investigated a calcium sulfate composite containing 
carboxymethylcellulose (CMC) or hyaluronan (HY) to improve CS’s handling or 
workability, mechanical, and degradation properties [31]. They showed that the 
introduction of these biopolymers allowed for better handling properties as well 
as increased compressive strength. Introduction of CMC and HY, however, had a 
drastic effect on the degradation rate of the composite. As the mass of CMC 
increased, the degradation rate also increased (12%/day for a loading of 10% 
CMC compared to 1.6%/day for plain CS) [31]. The purpose of the study was to 
develop a composite material with better handling abilities for insertion into a 
defect, however, the introduction of CMC and HY significantly increased the rate 
of dissolution, compromising the original absorption rate of calcium sulfate [31]. 
For the current study, the addition of 1 wt% PBAE gel particles did not have a 
significant effect on the dissolution rate of calcium sulfate (3.71%/day), and after 
increasing the amount of particles to 10 wt%, the rate of dissolution increased to 
4.42%/day. Gao et al. investigated the use of gelatin with calcium sulfate. In their 
study, the resulting degradation rates for calcium sulfate and their composites, 
4.3%/day to 5.2%/day, were similar to the rates observed in the present study for 
CS composites with embedded PBAE gel particles [91]. Another group 
investigated the use of calcium phosphate (CaP) microspheres within a CS 
matrix [105]. They were able to increase the retention time of the composite 
compared to blank CS, prolonging the absorption of CS in vivo. Urban et al. were 
also able to demonstrate a greater amount of bone formation over the course of 
26 weeks from the CS/CaP composite compared to the CS pellets alone [105]. In 
the present study, CS’s dissolution rate was not compromised by the 
incorporation of embedded gel particles. Using the original dissolution rate for 
CS, these embedded PBAE gel particles could perform as delivery vehicles for 
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bioactive drugs helping to increase the rate of tissue regeneration, thus possibly 
reducing the length of time needed for healthy bone to regenerate.  
3.4.3.1. Fluid Volume Effects 
The volume of fluid present during composite degradation in vivo is 
unknown, and the rate of fluid turnover is likely to have a notable effect on the 
rate of degradation. A degradation study utilizing multiple fluid volumes was 
performed to simulate the effects of different sink conditions that would result 
from different fluid volumes and/or turnover rates. The idea behind this 
experiment was to show the diversity of dissolution rates based on the volume of 
fluid possibly present in a particular wound site. In the case of implanting a CS 
composite in vivo, the rate at which the implant degrades will be key for proper 
resorption and replacement with healthy bone. As would be expected, smaller 
fluid volumes of 0.5 mL or 1.5 mL significantly reduced the rate of dissolution, 
0.6%/day or 2.7%/day, respectively. Conversely, increasing the fluid volume 
above 4 mL increased the rate of dissolution to about 6%/day. The similarity of 
the faster dissolution rates (6%/day and 6.6%/day) for fluid volumes ≥4 mL 
suggested a threshold for the sink conditions was reached that caused 
dissolution to become constant. Considering the surface area of the sample 
versus the volume of fluid used, it is fair to conclude that dissolution of cylindrical 
calcium sulfate samples with an estimated surface area of 114mm2 (assuming 
sample diameter of 4.66mm and height of 6.7mm) will be constant regardless of 
the volume used above the 3-4 mL threshold because of the limited amount of 
surface exposed. 
 
3.4.4. Composite Mechanical Properties 
Mechanical stability is important when developing a bone graft substitute 
material that will provide support for bone formation. Depending on the procedure 
performed, the majority of the graft could reside within a defect site where 
surrounding bony tissue would act as a protective shelter. The remaining portion, 
or cap, would protrude from the defect to provide both an aid for the vertical 
augmentation of bone, and to act as a ‘tenting apparatus’ distributing any load 
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from overlaid soft tissue while simultaneously preventing any ingrowth of soft 
tissue. An example of such a space-making site is the socket remaining after 
removal of a tooth. A graft placed into such a site (or a blood clot which fills the 
socket) will be protected and stabilized by the surrounding bony walls. 
A more challenging application would be sites that are not ‘space-making’, 
i.e., sites that lack topography to contain and protect the ‘regeneration chamber’. 
This would require development of implant materials that are strong enough to 
create and maintain space in the absence of any surrounding bone, and prevent 
soft tissue ingrowth while permitting new bone formation. The best example 
would be vertical bone growth in a badly resorbed mandible or maxilla. In the 
present study, CS composites were developed for this purpose. 
Gel loading of 1 wt% had a 10-20% decrease in the mechanical strength 
of the calcium sulfate composites. Because the 1 wt% HG loading ratio did not 
affect the dissolution rate, these composites may be preferable to blank calcium 
sulfate in clinical applications because of the added potential as a drug delivery 
vehicle. Addition of 10 wt% HG decreased calcium sulfate’s strength and 
stiffness by 50-60% and 70-75%, respectively, creating a much weaker 
composite. In this this study we considered 10 wt% HG an upper threshold for 
particle loading because of the potential adverse effects on the mechanical 
integrity. Any differences among the composite samples can be explained by the 
differences in their microstructure, e.g., stress concentrators formed by voids 
housing gel particles, minor microstructural defects, and growth and propagation 
of crystals as CS sets. In a study conducted by Kim et al., injectable calcium 
phosphate cements were developed [106]. Their compressive strength results for 
samples that contained 0-15 wt% of hydroxyapatite ranged between 2.5-4.5 MPa 
[106]. Interestingly, these results are similar to the compressive stresses 
witnessed in the present study. Blank CS, 1 wt%, and 10 wt% gel samples 
resulted in compressive stresses around 5.5, 4, and 2 MPa, respectively.  
Lewis et al investigated the compressive strength of their biopolymer/CS 
composites material [31]. Their blank calcium sulfate samples had a 10 MPa 
compressive strength that was stronger than the present results. An interesting 
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aspect of biopolymer/CS composites compared to HG/CS was the similarity in 
the amount of fluid that was used for production compared to the differences 
found in the resulting mechanical strengths. The fluid to powder ratio of Lewis et 
al. ranged between 0.8-1.33 mL/g compared to 0.8-0.9mL/g found in the present 
study [31]. Another group investigated the use of an α-hemihydrate CS for a 
composite structure incorporating biomimetic apatite nanoparticles for controlled 
drug delivery [99]. That study utilized two liquid to powder ratio, 0.6 and 0.4 mL/g. 
Although these ratios were lower than those used in Lewis’ study or the present 
study, the compressive strength of CS (2-4MPa) was comparable [99]. The 
similarities in compressive strength help demonstrate that the liquid to powder 
ratio does not appear to have a significant effect on the strength of the material 
within the ranges presented. An attempt to optimize liquid content and/or loading 
of gel particles to achieve a desired grafting device will be investigated in the 
future. 
 
3.4.5. Curcumin Pilot Release 
 As a naturally occurring drug originating from the dietary spice turmeric, 
curcumin has a broad range of therapeutic functions which include anti-
inflammatory, antioxidant, anti-bacterial, and more recently, anti-resorptive [52, 
102, 107]. Groups have investigated curcumin’s ability to reduce or prevent the 
resorption of bone. Ozaki et al. studied curcumin’s effects on osteoclast 
apoptosis in rabbits [107]. Their findings concluded that curcumin does play a 
significant role in osteoclast apoptosis, and furthermore, were able to 
demonstrate the inhibitory effects of osteoclastic bone formation [107]. Early 
exposure of a multi-functional drug that was controllably released from the 
proposed CS composites could significantly reduce alveolar bone regeneration 
time due to the lack of other complications produced by inflammation and/or 
bone resorption. This would in turn allow for a much earlier application of a dental 
prosthesis restoring normal function.  
A pilot study to demonstrate the controlled or sustained release of a drug 
from CS composites was conducted by releasing curcumin from curcumin-loaded 
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PBAE gel particles embedded within a CS matrix. Over 28 days, the release of 
curcumin was monitored. As per the results of this experiment 1 wt% HG loaded 
composites showed a sustained release of drug with a slow decay in the daily 
rate of release. 10 wt% HG had a much greater burst of drug during the first 4 
days (~50%), but over the course of the final 24 days the release was sustained. 
Continuous dissolution of CS permits only the PBAE particles that are exposed to 
the surface of the composite to break down, and therefore, allowing the drug to 
be released. According to the curcumin release investigated in Wattamwar’s 
study, the antioxidant was directly incorporated into the PBAE macromer prior to 
polymerization [102].  This process helps prevent the premature release or 
diffusion of drug from the gel matrix prior to hydrolysis allowing for further 
controlled release of curcumin [102].  Additionally, during the dissolution process 
the total exposed surface area slowly decreases which in turn only allows a 
smaller volume of exposed particles overtime to breakdown and release the 
drug. This trend helps explain the slow decay in the daily rate of curcumin 
release, and furthermore helps establish the fact that the release of curcumin 
from HG particles is controlled by the way HG is released during dissolution of 
CS composites.  
 
3.5. Conclusion 
 Calcium sulfate-based composites with embedded poly(β-amino ester) 
biodegradable gel particles were developed to potentially serve as a bone graft 
substitute for vertical bone regeneration. The gel particles are intended to provide 
the eventual delivery of bioactive molecules to enrich the bone augmentation 
process without physically compromising the capacity of the composite to be 
used as a grafting substitute. It was determined that the PBAE gel particles were 
uniformly distributed within the CS matrix, and the embedded particles had 
minimal impact on the zero-order dissolution rate. However, from a destructive in 
vitro dissolution study, it was shown that fluid volume turnover will have a large 
effect on the rate at which these composites will degrade. It was also determined 
the PBAE particles did have a significantly negative effect on the mechanical 
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strength of the composites. As much as a 75% drop in its strength was seen with 
a 10 wt% loading of particles. On the other hand, since the dissolution rate was 
minimally affected with the increased loading of gel particles, and the composites 
are designed to have an effective osteogenic drug delivery capability to help 
enhance tissue regeneration. Additionally, the decrease in strength does not rule 
out their potential to be a useful synthetic bone graft substitute for vertical ridge 
augmentation. A pilot release study of curcumin from particles embedded within 
the composites demonstrated a sustained release of the drug that was governed 
by the degradation of embedded partilces during the dissolution of CS over time. 
Futher developments will investigate the composite bone graft substitute’s 
capacity to deliver a broad range of drugs and their capability to be tailored on a 
case by case basis.  
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Chapter 4:  Drug Release from Calcium Sulfate-Based Composites 
 
4.1. Introduction 
Bone augmentation through the application of onlay autogenous bone 
grafts is a suitable method for vertically restoring maxillofacial bone defects [43, 
44, 89, 108-112].  Although autografts are considered the ‘gold standard’ for 
augmentation procedures, they have multiple disadvantages as well.  Their 
availability from intra-oral donor sites is limited, and harvesting tissue, which 
requires a secondary surgery, can lead to undesirable donor site morbidity and 
chronic discomfort [31, 37, 84, 88-96].  Many groups are developing synthetic 
grafting substitutes to replace the current standard.  In doing so, several 
performance criteria must be met.  The synthetic bone graft substitute needs to 
be biocompatible, osteoconductive to help create a secure bond with the 
surrounding host tissue, and mechanically stable to ensure that vertical 
augmentation can be achieved without collapse [22, 51, 113].  Calcium sulfate 
(CS) hemihydrate has an excellent reputation as a biocompatible and 
osteoconductive substance [31-35, 46]. In vivo, calcium sulfate becomes 
osteogenic in the presence of bone and is completely absorbed without inducing 
a significant inflammatory response [31, 33-35, 46].  In addition, CS is 
mechanically similar to cancellous bone [38].  
Although synthetic grafting alternatives, such as CS, can be effective, their 
osteoconductive properties may be improved through the aid of bioactive agents 
like growth factors or other osteogenic agents capable of inducing new bone 
formation [45].  Studies have shown synthetic bone grafts enhanced through the 
release of bioactive molecules [45-47].  An ongoing question relates to how these 
molecules can be delivered to maximize their therapeutic potential [62].  One 
possible approach is to load drug directly into a CS construct.  If uniformly 
distributed throughout the matrix, dissolution of CS will result in release of the 
drug.  Based on release of fibroblast growth factor, Rosenblum et al. concluded 
that CS could be a suitable carrier for sustained drug delivery [46].  Another way 
to load drug is through the aid of carrier particles.  Biodegradable hydrogel 
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networks provide specific advantages for drug delivery due to their high water 
content, general biocompatibility, and controlled degradation via hydrolysis or by 
enzymatic degradation leading to controlled drug delivery [62, 65, 78].  In 
particular, the poly(β-amino ester) (PBAE) family of hydrogels has properties that 
are easily tuned to achieve great control as a drug delivery vehicle [66, 71, 78].  
Previous research has shown that PBAE particles can be uniformly embedded 
into a CS matrix, which may allow further control over the release of drug from 
these particles as the CS matrix erodes [113].    
Several osteogenic drugs are available.  These range from larger proteins, 
such as bone morphogenetic proteins (BMPs; 30-38 kDa) down to small 
molecules, such as the statin family of drugs (<1 kDa).  BMPs control tissue 
induction and morphogenesis and are directly involved in the differentiation of 
cartilage and bone [49-51].  Introducing BMPs into grafting devices can stimulate 
rapid new bone formation, allowing for a reduction in healing time to achieve 
sufficient new bone volume for proper anchoring of an inserted implant [47, 52].  
Like all statins, simvastatin (419 Da) is commonly known as an inhibitor of 3-
hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase and often 
prescribed to control cholesterol levels [55, 56].   Importantly, however, 
simvastatin promotes bone formation in vitro and in vivo through the stimulation 
of osteoblastic activity and inhibition of osteoclastic activity [55, 56].  Due to its 
pharmacokinetic characteristics of being actively cleared in the liver, controlling 
the local release of relatively higher amounts of simvastatin from a synthetic 
bone graft can maintain a therapeutic level of drug suitable for accelerated bone 
regeneration [56]. 
In the present study, previously developed CS-based composites were 
investigated for their ability to control the release of drugs [113].  A larger 
hydrophilic protein and a smaller hydrophobic molecule were evaluated to 
demonstrate that a range of osteogenic drugs could be released from the 
composites, either loaded in hydrogel particles or directly loaded into the CS 
matrix.  The study will investigate how the solubility and other characteristics will 
affect the way the agents are loaded into CS to achieve a controlled and 
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consistent release.  Lysozyme was chosen as a model protein to determine the 
potential to adjust protein release, and simvastatin was used as a representative 
small molecule drug. 
 
4.2. Materials and Methods 
4.2.1. Hydrogel synthesis 
H6 PBAE macromer was synthesized according to previously described 
methods [78, 113].  To review, polyethylene glycol (PEG) 400 diacrylate 
(Polysciences, Inc., Warrington, PA) and isobutylamine (Sigma-Aldrich, St. Louis, 
MO) were combined in a 1.2:1 molar ratio and placed in a flask partially 
submerged in a silicon oil bath pre-heated to 85°C.  The reaction mixture was 
continuously stirred for 48 hr and thenremoved from the heat. The resulting 
macromer was stored at 4°C until used.   
Biodegradable hydrogels (HG) were made by photopolymerization.  Two 
grams of cooled macromer and 1 wt% of 2,2-dimethoxy-2-phenyl-acetophenone 
(DMPA; Sigma Aldrich, St. Louis, MO) initiator were dissolved in 1.25 mL of 
dimethyl sulfoxide (DMSO).  H6 loaded with lysozyme was made the same way 
except that 100 mg of lysozyme (14 kDa; Sigma-Aldrich; solubility: ~300 mg/mL 
in H2O) was added along with the initiator.  After vortexing for 60 sec, the 
homogeneous mixture was pipetted in between glass plates separated by a 1.5 
mm Teflon spacer .  The macromer was exposed to UV radiation from a Lesco 
UV flood source with an intensity of 14 mW/cm2 for 5 min starting at room 
temperature.  After polymerization, the gel was washed with ethanol for 30 
minutes to remove any unreacted initiator and macromer and then lyophilized 
overnight.  
 
4.2.2. Protein release from H6 PBAE gels 
 To assess release kinetics from the gel alone, circular (diameter: 9 mm) 
samples of protein-loaded H6 PBAE were weighed, submerged in 4 mL of PBS, 
and incubated at 37°C on a plate shaker.  For the first hr, supernatant was 
collected for measurement and replenished every 10 min. During the second and 
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third hr, supernatant was collected and replenished every 20 min. After 3 hr, the 
time intervals were increased to every hr until the samples completely degraded.  
Collected supernatant was measured using the MicroBCA Protein Assay 
(Thermo Fisher Scientific, Rockford, IL) according to the manufacturer’s protocol. 
 
4.2.3. Formation of drug-loaded calcium sulfate composites  
The composites consisted of calcium sulfate hemihydrate (Sigma-Aldrich) 
as the structural matrix and different amounts of lysozyme-loaded HG particles.  
Hydrogel particles were hand-ground from polymerized gel slabs using a mortar 
and pestle at room temperature.  In order to coat the gel particles and prevent 
them from sticking to one another, as well as to allow grinding to be efficient, 
small amounts of CS powder were added during grinding.  Particle sizes of 53-
150 μm and 150-250 μm were obtained from grinding and sieving.  After 
grinding, gel particles were washed with 100% ethanol for 1 min to remove 
residual CS, filtered, and air-dried.   
CS samples were fabricated as previously described.[113]  Briefly, control 
(drug- and HG-free) CS samples were made by thoroughly mixing 1 g of CS 
powder and 800 µL of deionized (DI) water in 3 mL syringes fitted with blunt-
tipped needles.  The slurry was loaded into a custom Teflon mold having a 
diameter of 4.7 mm and a height of 6.5 mm and allowed to set at 43ºC for 24 hr.  
Similar to the CS control samples, 1 wt% composite samples were created by 
mixing 0.01 g HG particles with 0.99 g CS and 850 µL DI water.  Samples with 10 
wt% protein-loaded particles were made by mixing 0.1 g HG, 0.9 g CS, and 900 
µL DI water.  As for the controls, the composite mixtures were also allowed to set 
at 43ºC for 24 hr.  CS samples directly loaded with lysozyme were also made for 
comparing with protein release from CS-HG composites.  Two different loadings 
were selected to match the amounts in hydrogel composite samples.  Briefly, 500 
μg or 5 mg of lysozyme were mixed with 1 g CS powder and 800 μL DI water to 
create the low and high loadings, respectively. The slurries were loaded into a 
mold and allowed to set at 43°C for 24 hr. 
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Simvastatin-loaded samples were created by adding 20 mg of simvastatin 
(Haouri Pharma-Chem, Inc., Edison, NJ; 419 Da; solubility: 12.2 μg/mL in H2O) 
to 1 g of CS powder prior to mixing with 850 μL of DI water.  The slurry was 
injected into a custom-fabricated Teflon mold and placed in a 43ºC oven for 24 hr 
to set the CS. 
 
4.2.4. Surface exposure of HG particles on CS surface 
To visually demonstrate the surface exposure of protein containing HG 
particles at the surface of CS during dissolution, samples were produced 
containing gel particles dyed with blue food coloring.  HG particles (150-250 μm) 
were fabricated using the same methods described above for gel polymerization 
and grinding.  The finished gel particles were soaked for 5 mins in a 1 mL 
solution of DI and 3 drops of blue food coloring.  After 5 mins, the particles were 
washed and vacuum filtered.  The washed particles were quickly frozen at -80°C 
and lyophilized overnight.  To produce the CS composites, methods for 
composite fabrication described above for a 10 wt% HG loaded samples were 
used.  Photographs were taken using a Canon DS126071 camera fitted with a 60 
mm macro lens prior to exposure to PBS and after 24 hr of dissolution in 4 mL 
PBS.             
 
4.2.5. Drug release from CS samples 
 Protein release from CS composites was conducted with samples for each 
treatment (blank, 1%HG 53-150 μm, 10%HG 53-150 μm, 1%HG 150-250 μm, 
10%HG 150-250 μm, direct low, and direct high) initially weighed, submerged in 
4 mL of PBS, and incubated at 37°C on a plate shaker.  Every 4 days, 
supernatant was collected for measurement and replaced with 4 mL of fresh PBS 
until all samples had completely degraded.  Collected supernatant was measured 
using the MicroBCA Protein Assay slightly modified from the manufacturer’s 
protocol due to CS precipitation observed when the working reagent was added.  
Briefly, 200 μL of supernatant and 200 μL of working reagent were combined and 
incubated at 37°C for 2 hr.  Vials were centrifuged at 10,000 G for 2 min to 
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separate any CS precipitate that formed during incubation, and absorbance of 
the cleared reagent was measured at 562 nm.  Lysozyme standards were also 
assayed using this process to allow for consistent results.  
Simvastatin release was conducted by pre-weighing both blank and 
simvastatin-loaded CS samples, submerging them in 4 mL of PBS, and 
incubating at 37°C on a plate shaker.  Every 4 days, supernatant was collected 
for measurement and then replenished with 4mL of fresh PBS.  The collected 
supernatant was treated with 100% ethanol in a 50:50 volume ratio of 
supernatant to solvent.  After filtration (0.45 μm), absorbances were measured at 
240 nm and compared to a series of standards. 
 
4.2.6. Mechanical properties 
Compression testing was performed to determine whether incorporation of 
directly loaded drug (simvastatin and lysozyme) or protein-loaded H6-PBAE 
particles into CS would affect the mechanical properties.  Testing was conducted 
using a Bose ELF 3300 system. Contact surfaces were lightly sanded, if 
necessary, using 600 grit SiC paper to provide smooth, parallel surfaces in 
contact with the compression platens. Control (blank, drug-free), directly loaded 
simvastatin, low and high dose of directly loaded lysozyme, 1 wt%HG, and 10 
wt%HG samples were tested at a rate of 0.5 N/sec until failure. Compressive 
modulus (M) and ultimate compressive strength (UCS) were calculated. 
 
4.2.7. Statistics 
Statistical analysis of the mechanical compression results was performed 
using two-way ANOVA. As appropriate, the analysis was followed with a Tukey-
Kramer multiple comparisons post hoc test. Differences between groups were 
considered to be significant with p-values < 0.05.  
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4.3. Results 
4.3.1. Protein release from H6 PBAE gels 
 Figure 4.1 displays the kinetics of lysozyme release from H6 PBAE discs.  
During the first hr, the gels swelled steadily with little protein (~4.5%) being 
released.  For the next two hr, the rate of protein release continued to increase 
from 13% per hr to a steady state of 22.8% per hr, which was sustained for the 
remainder of the experiment. After four hr, the gels became too difficult to handle, 
and consequently the degree of swelling could not be determined. 
 
4.3.2. Surface exposure of HG particles on CS surface 
 Figure 4.2 shows a couple photographs displaying hydrogel particles 
exposed at the surface of CS composites.  The left photo shows a freshly made 
composite.  HG particles appeared to be uniformly distributed at the surface.  
After a day of dissolution (right image), the top layer of gel had degraded leaving 
behind pockets in the CS (right photo insert).   
 
4.3.3. Protein release from composites  
Displayed in Figure 4.3 are the results for the release of lysozyme directly 
loaded into CS.  For the lower loading, no protein was released during the first 4 
days (Figure 4.3A).  From 4-16 days, release was fairly steady at a rate of 
4.5%/day, and at day 16, the rate decreased to about 1.4 %/day. During the final 
4 days, the rest of protein was released at a rate of 8.7%/day.  However, large 
variations in release were observed; fluctuations as high as ±30%/day were 
seen.  The instantaneous release pattern was erratic and unpredictable.  Figures 
4.3B show results for samples with the high direct loading of protein.  A large 
burst (~65%) of protein was observed, after which release was fairly steady at a 
rate of 1.15%/day with some fluctuations.  The high direct loading also showed 
large deviations (±15-20%/day) among the samples. 
Figure 4.4 shows the release kinetics for CS composites containing 
embedded PBAE particles loaded with lysozyme. A steady release of lysozyme 
from 1 wt% HG composite loadings (both particle sizes) was observed, where a 
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30-40% burst of protein was measured during the first 4 days, and 70-80% of the 
protein was released after 14 days (Figure 4.4A). The rate of protein release from 
1 wt% HG samples slowly decayed over the duration of the experiment.  At the 
beginning, the average rate of release was as much as 7-10%/day at 4 days, 
while at later time points, the average rate decreased to 5-7%/day at 12 days and 
4%/day at 24 days. On the other hand, for composites loaded with 10 wt% HG, 
release started with a much larger burst of protein (55-70%) at an average rate of 
about 17%/day during the first 4 days followed by 80-90% being released during 
the first 12 days of the 24 day study (Figure 4.4B). After about 8 days, release 
remained fairly steady at an average rate between 0.5% and 3% per day.   
 
4.3.4. Simvastatin release from calcium sulfate  
Figure 4.5 illustrates the release kinetics for CS composites directly 
loaded with simvastatin. There appeared to be a short delay in the initial release 
of simvastatin, and over the first 8 days, roughly 12% of the drug was released.  
Following this lag period, the average rate shifted upward to about 5.5% of 
simvastatin per day and remained steady between days 8 and 20.  After 20 days, 
release slowed to 3%/day and remained close to this rate for the final 8 days of 
the 28 day study.   
 
4.3.5. Mechanical properties 
For the ultimate compressive strength, Figure 4.6A, CS blanks were 
significantly stronger than samples with the high dose of directly loaded lysozyme 
(p<0.01), 1 wt% HG composites (p<0.001), and 10 wt% HG composites 
(p<0.001).  The strength of 10 wt% HG (1.0 ± 0.3 MPa) compared to CS blanks 
(5.5 ± 0.6 MPa) was about 80% weaker.  Compared to all drug loaded samples, 
the strength of 10 wt% HG was also significantly lower than all other samples 
(p<0.001).  In addition, the decrease in strength for the high direct loading of 
lysozyme (4.3 ± 0.5 MPa) and 1 wt% HG composites (4.1 ± 0.4 MPa) was only 
about 20-25% compared to the CS blanks.   
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The elastic modulus, Figure 4.6B, for CS blanks (406 ± 126 MPa) was 
significantly higher than that for directly loaded simvastatin samples (267±68 
MPa) and 10 wt% HG composites (189 ± 89MPa) (p<0.01).  There were no 
significant differences between the controls and low direct lysozyme, high direct 
lysozyme, and 1 wt% HG composite samples.  Elastic modulus for 10 wt% HG 
composites was also significantly less than that for low direct lysozyme (430 ± 
154 MPa; p<0.001), high direct lysozyme (349 ± 110 MPa; p<0.05), and 1 wt% 
HG composites (383 ± 126 MPa; p<0.01).    
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FIGURE 4.1. Lysozyme release from PBAE gels along with the swelling profile of 
H6 PBAE.  Data are mean ± standard deviation (n=3). 
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 FIGURE 4.2. Photograph depicting HG surface exposure on CS composites.  HG 
particles dyed blue for contrast. (Left) Sample before 24 hr dissolution in PBS. 
(Right) Sample after 24 hr in PBS.  
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A.  
B.  
FIGURE 4.3. Release of lysozyme directly loaded into CS.  (a) Cumulative profile 
for the low protein loading.  (b) Cumulative profile for the high protein loading. 
Data are mean ± standard deviations (n=5). 
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A.  
B.  
FIGURE 4.4. Cumulative release of lysozyme from CS composites having two 
different HG particle sizes (53-150 μm and 150-250 μm).  (a) 1 wt% HG and (b) 
10 wt% HG. Data are mean ± standard deviations (n=5). 
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FIGURE 4.5. Cumulative release of simvastatin directly loaded into CS. Data are 
mean ± standard deviation (n=5). 
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A.  
B.  
FIGURE 4.6. Mechanical properties of simvastatin- and protein-loaded CS. (a) 
Compressive strength; (b) Compressive elastic modulus. Data are mean ± 
standard deviation (n=10). Symbols (*) and (#) indicates significant difference: 
p<0.01and p<0.05, respectively. 
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4.4. Discussion 
The aim of the present study was to demonstrate that previously 
developed CS composites[113] are capable of controlling the release of different 
bioactive molecules having a broad range of physical and chemical properties 
such as size, function, and solubility by utilizing either direct loading of drug into 
the CS matrix or with the aid of PBAE hydrogel particles. 
 
4.4.1. Protein release from H6 PBAE gels 
 H6 PBAE particles were investigated as a drug delivery vehicle embedded 
in a CS matrix.  For this study, gel particles were loaded with the protein 
lysozyme.  Lysozyme, an extensively studied and characterized protein, has 
become a reliable substitute for larger osteogenic molecules, such as bone 
morphogenetic proteins [114, 115].  A study of protein release directly from the 
gel was conducted first.  After a slow initial release of lysozyme, a higher steady 
state was sustained for the remainder of the experiment.  The overall trend 
suggested that lysozyme was trapped within the gel allowing only a slow diffusion 
of protein from the matrix during swelling followed by protein being released as 
the gel degraded.  This was desired for allowing release of protein from the 
composites to occur only when the gel particles are exposed and released 
themselves.  
 Hawkins et al. demonstrated sustained release of lysozyme from A11 
poly(β-amino ester) [116].  The method for loading lysozyme in the A11 PBAE 
gels was similar to that used with H6 PBAE gels in this study.  Although the two 
polymers have different compositions, they also have some similarities as 
members of the PBAE family of hydrogels [66, 71, 77, 78, 116].  Among this 
family of materials, a variety of possible combinations of diacrylates and amines 
can produce similar range of properties [66, 71, 77, 78, 116].  The similarities 
between these two PBAEs demonstrate the adaptability of this gel family to 
accommodate different formulations or drug types if needed.   
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4.4.2. Protein release from CS  
To determine the effectiveness of controlling release of protein from CS, a 
series of release experiments compared release of lysozyme from composites to 
release of protein directly loaded into the CS matrix.  To allow for an accurate 
comparison, the lysozyme amount for 1 wt% HG was matched with the low direct 
loading, and the loading for 10 wt% HG was the same as that for high direct 
loading.  Two different release trends were seen for direct loading.  During the 28 
day study for the lower direct loading of lysozyme, the amount of protein released 
fluctuated with no noticeable consistencies.  In addition to this variability, there 
was a delay in the release of protein during the first 4 days.  Although the 
cumulative release for the lower direct loading showed an overall linear trend, 
there were large deviations from the means, which may indicate inhomogeneous 
distribution of protein within and between samples. When comparing the low 
direct loading to the 1 wt% HG samples, release of lysozyme from the 
composites was more consistent.  Previous research demonstrated good gel 
particle distribution in the composites [113].  The slow decay in the release of 
protein from the 1 wt% HG composites was similar to that observed for a pilot 
study with the antioxidant curcumin [113]. An important difference from the 
curcumin release study was that the drug was previously added during PBAE 
macromer synthesis, which allowed it to covalently bind with the diacrylate [102].  
This process helped prevent premature release or diffusion of drug from the gel 
matrix prior to hydrolysis, providing greater control over curcumin release [102].  
Instead of being covalently incorporated during macromer synthesis, the 
macromer was polymerized around the protein in the present studies.  Because 
lysozyme is a much larger molecule, the protein could be entrapped in the 
polymer mesh structure.  This trapping of protein allows release from the gel 
matrix only after particles near the surface of the dissolving CS have been freed 
and begun to degrade.  As discussed in section for protein release from H6 
PBAE gels, protein was prevented from leaving the gel matrix until the gel 
showed signs of hydrolysis.  This illustrates that protein was not prematurely 
released prior to exposure of HG particles during composite erosion.  Based on 
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the images displaying HG particles (dyed blue) embedded into CS, the gel 
particles that were at or very near the surface had degraded leaving behind small 
pockets in the CS, which in turn began to expose more blue colored gels below 
the surface.  This observation helps to demonstrate how the release of protein 
from embedded HG particles is governed by CS dissolution.  In addition, in a 
previous study, MicroCT images showed a uniform distribution of HG particles 
throughout a CS matrix which could allow for a sustained release as CS 
dissolved [113].  The slow decay in the release of protein from the 1 wt% HG 
composites can be attributed to the slow decrease in surface area of CS over the 
duration of the release study, which leads to a smaller amount of gel particles 
exposed over time and thus a slowly decreasing mass of protein being released.      
 The two different higher loadings (high direct and 10 wt% HG) 
demonstrated similar release kinetics.  However, the advantage for the 10 wt% 
composites was the smaller variability among samples and therefore better 
control of protein release.  During the first several days of the release, a large 
surface area of CS was exposed, allowing for a much larger volume of gel 
particles to be released.  This could lead to an accumulation of gel particles 
releasing protein early on and thus contribute to the burst witnessed from the 10 
wt% HG composites.  As for the high direct loading of lysozyme in CS, greater 
early protein release could result from a segregation effect due to solubilized 
protein accumulating at the surfaces in excess water as the CS slurry sets.  
Furthermore, as water was consumed by reaction from the hemihydrate to 
dehydrate forms of CS, some solubilized protein may be precipitated and trapped 
within the setting matrix.  The more variable release of protein could be attributed 
to a heterogeneous distribution of lysozyme among the CS matrix potentially 
caused by protein aggregation, CS crystal formation causing closure of small 
pockets containing larger amounts of protein, and/or poor mixing of protein and 
CS before and after addition of water.  With the addition of carrier particles, such 
as protein-loaded PBAE, the variations can be reduced or eliminated altogether.   
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4.4.3. Simvastatin release from CS  
To demonstrate the release of small molecule osteogenic agents, 
simvastatin was directly loaded into CS.  Ginebra et al. described how drug may 
be trapped between crystals in a ceramic matrix; dissolved in the liquid within 
pores, adsorbed to the crystal surface, or in solid form as drug crystals [117].  
Because simvastatin has low water solubility, the drug was likely to be 
suspended in the CS slurry and not dissolved in the water.  With this in mind, as 
water was consumed during setting or excess water was driven to the exterior of 
the samples, simvastatin remained in the CS matrix.  As a result, the drug was 
released as the material dissolves with consistent results.    Based on the ability 
to control release by directly loading simvastatin in CS, incorporating the drug in 
hydrogel particles is unnecessary and would introduce unneeded material in the 
system.   
Nyan et al. also investigated simvastatin directly loaded into CS.  They 
conducted an in vivo study in critically-sized rat calvarial defects [45].  A dramatic 
increase in bone volume was observed after 8 weeks, which was significantly 
greater than for any other group [45].  However, substantial soft tissue 
inflammation was also observed during the first several weeks, and the authors 
concluded that this was most likely caused by a burst release of simvastatin 
following early resorption of CS [45].  Although dissolution of the implants was 
not assessed, the present results support the hypothesis that rapid erosion of CS 
would release a burst of drug.     
 
4.4.4. Mechanical properties 
With the incorporation of drug either directly loaded or in PBAE particles 
embedded in CS, compromise of mechanical stability can become a concern.  
The present drug-loaded composites are being developed as bone graft 
substitutes with tunable drug delivery capabilities.  With this in mind, it is 
important to note that much of the strength of the grafting device must be 
preserved to allow for a stable implant capable of providing a suitable ‘healing 
chamber’ for tissue regeneration as well as allow for controlled release of drug as 
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the implant dissolves.  A previous study demonstrated that the addition of 
additives did not have a dramatic effect on the dissolution of the composite, 
therefore the attention is drawn to the preservation of the mechanical strength of 
the composites [113].  In the present study, the comparison of compressive 
properties for CS with directly loaded simvastatin to those for blank CS showed 
that the drug did not have a significant effect on the overall strength.  However, 
incorporation of simvastatin reduced the modulus about 30% compared to the 
CS control samples.  Although a small molecule drug, simvastatin may be 
creating small disruptions in the CS crystal interactions that could lead to greater 
shearing along crystal surfaces resulting in more deformation prior to failure.  Yin 
et al. reported that a small amount (10%) of directly loaded simvastatin did not 
significantly compromise the compressive strength of calcium phosphate [118].  
In the current study, 20 mg, or 20 wt%, was loaded into CS prior to sample 
production.  Although the materials were different, this finding demonstrates that 
the incorporation of a small amount of simvastatin does not appear to affect the 
supporting material, thus preserving its overall strength.  
The effect of loading a much larger drug molecule compared to 
simvastatin on the mechanical stability of CS was also tested. Protein, i.e., 
lysozyme, was either directly loaded into the CS matrix or it was polymerized into 
H6-PBAE hydrogel particles that were then incorporated into the CS.  Directly 
loading lysozyme into the CS matrix at the amounts tested did not have much of 
an effect on the overall mechanical properties.  Addition of HG particles, 
however, did affect the mechanical stability of CS.  The significant decrease in 
strength and modulus for 10 wt% HG particle loading demonstrates a possible 
limit to the amount of drug-loaded particles that can be added.  In a previous 
study, Orellana et al. showed that the addition of 10 wt% of A11 PBAE particles 
decreased the strength and modulus of CS by 50% and 70%, respectively [113], 
which suggested a comparable upper threshold of particle loading.  A potential 
explanation for the particle loading effect could be contributed to the altered 
microstructure due to stress concentrators created by the gel particles or even 
minor bubbles/pores [113].  For a drug delivery platform that not only preserves 
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as much of the mechanical stability of CS as possible but also allows controlled 
release of drug as the material erodes, a loading of 1 wt% HG may be 
considered the better option based on the results observed in the mechanical 
tests and the consistency witnessed for the release of a larger hydrophilic 
molecule.    
 
4.5. Conclusion 
 Controlled release of bioactive molecules has the potential to greatly 
enhance the ability of calcium sulfate-based composites to become more 
effective bone graft substitutes.  In the present study, release kinetics were 
investigated for two different agents, a small, hydrophobic drug and a much 
larger, hydrophilic protein, incorporated into CS.  Controlled release of both 
molecules could be achieved but by different means.  Whereas direct loading 
was appropriate for simvastatin, control of lysozyme release required 
incorporation of the protein in degradable polymeric particles prior to embedding 
in CS.  Adding a drug, either directly into CS or via PBAE particles, however, can 
negatively affect mechanical properties.  In particular, greater amounts of gel 
particles significantly reduced compressive strength and modulus.  Therefore, the 
balance between drug content and mechanical properties must be determined for 
different applications.  Based on the current findings, CS-based synthetic bone 
graft substitutes demonstrated the ability to sustainably release both large and 
small bioactive molecules, opening up potential opportunities to deliver a broad 
range of therapeutic agents. 
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Chapter 5:  Tailored Sequential Drug Release from Bilayered Calcium 
Sulfate Composites 
 
5.1. Introduction 
Healing of infected bony defects, such as those resulting from periodontal 
disease, has become a major focus in the field of bone tissue engineering [119].  
Onset of periodontitis, a bacterial infection affecting the gingiva, alveolar bone, 
periodontal ligament, and root cementum, leads to the initiation and propagation 
of chronic inflammation, eventually causing the destruction of surrounding 
connective tissue and bone [8, 10, 14, 120-122].  Periodontal infections are first 
treated with extensive debridement and scaling of plaque [8, 14, 121, 123].  
Some pathogens may not be susceptible to mechanical removal, however, 
because they often ‘hide’ deep in gingival pockets around compromised bony 
tissue [14, 124].  These bacteria can frequently trigger reoccurrence of the initial 
infection, which greatly affects restoration or preservation of lost bone [123].  
Antibiotics systemically delivered orally or locally administered using topical gels, 
creams, or films are then used to eliminate the pathogens prior to implantation of 
grafting material [14, 119, 123].   
An infected periodontal pocket contains an abundance of microflora, such 
as Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis [14, 
15].  These pathogens are often protected within a biofilm, which allows them to 
flourish and requires a substantially higher dose of antibiotic to fully eradicate the 
bacteria [14, 15].   Due to clearance in the blood during systemic administration, 
the resulting low local concentrations of antimicrobial agents at the infected site 
often do not meet the levels required to kill the microbes [120-122, 125].  As a 
result, long-term therapy with high systemic doses of antimicrobial agents may 
be needed to fully eliminate the infection.  However, this treatment could 
potentially cause adverse effects, such as liver and kidney damage, or lead drug 
resistance [126].  Consequently, local administration of drug directly to the site of 
infection may prove more effective by providing a higher concentration while 
using a smaller dose [14, 121].  Of the different antibiotics used for dental 
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applications, metronidazole significantly reduces periodontal infection when 
compared to others [63, 125].  In addition, using a biodegradable material 
capable of controlling the amount of metronidazole released may allow for higher 
sustained and more effective concentrations to be obtained at the site.   
Following treatment of periodontal infections, regeneration of bony tissue 
can begin.  Bone regeneration using autografts is considered the ‘gold standard’.  
Intra-oral donor sites are limited, however, and harvesting can lead to 
undesirable donor site morbidity and chronic discomfort [31, 37, 45, 54, 64, 84, 
88-96].  Another option is the use of allografts harvested from cadaveric bone 
tissue.  Although frozen, freeze-dried, and/or demineralized, patients receiving 
the grafts are still at risk of immunologic rejection or disease transmission [56, 
64, 127].  Allografts have been combined with osteoinductive growth factors to 
make them more effective [45].  Because of the limitations, and even risks, 
involved with autogenous and allogeneic materials, much attention has turned to 
the development of innovative bone graft substitutes.  Calcium sulfate (CS) 
represents a promising alternative [45].  CS becomes osteogenic in the presence 
of bone, and through dissolution, the material is completely absorbed without 
inducing a significant inflammatory response [31, 33-35, 46]. Like many other 
synthetic grafting alternatives, however, the efficacy of CS can be further 
enhanced with the aid of bioactive agents.   
A beneficial addition would be the incorporation of statin drugs.  Statins 
are widely known as inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-
CoA) reductase that help control cholesterol levels, but these pleiotropic drugs 
also have osteogenic activity [55-57, 59, 60, 128, 129].   In vitro and in vivo 
studies have demonstrated the positive effects of simvastatin through stimulation 
of osteoblastic activity and inhibition of osteoclastic activity [55-59, 128, 129].  
Simvastatin was shown to be effective when released from a CS matrix in vivo 
[45].   
A bone grafting device capable of sequentially releasing an antibiotic 
followed by an osteogenic agent may be able to treat infection while still being 
able to regenerate bone.  Little research has investigated the release kinetics of 
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antimicrobial and osteogenic drugs from the same grafting device [119].  In the 
present study, dual drug-loaded, bilayered CS composites comprising a shell and 
core geometry with embedded poly(lactic-co-glycolic acid) (PLGA) particles were 
developed.  After evaluating the compressive strength and modulus, dissolution, 
and morphology of bilayered composites, the tunable sequential release kinetics 
of metronidazole and simvastatin from the composites were explored.  
 
5.2. Materials and Methods 
5.2.1. Metronidazole-loaded PLGA Particles 
Poly(lactic-co-glycolic acid) (Durect Corp., Birmingham, AL; 50:50; 
inherent viscosity: 0.55-0.75 dL/g; carboxylate end group) particles loaded with 
metronidazole (Sigma-Aldrich, St. Louis, MO) were created by film-casting and 
hand-grinding.  Initially, 25 mg of metronidazole were combined with 200 mg of 
PLGA and dissolved in 1 mL of dimethyl sulfoxide (DMSO; an FDA Q3C Class 3 
solvent).  The solution was poured into a circular Teflon mold, frozen quickly at -
80°C, and lyophilized to remove the DMSO.  The dried film was hand ground to 
obtain particle sizes between 150-250 µm.  A small amount of CS was used to 
prevent the polymer from sticking during grinding.  The particles were washed 
with ethanol to remove residual CS powder on the surface of the polymer.  
Ethanol was chosen for washing to prevent drug loss because the low solubility 
of metronidazole in this solvent.  Washed particles were vacuum-filtered, rapidly 
air-dried, and stored at -20°C until used. 
A short-term study of metronidazole-loaded microparticles was conducted 
to determine how much drug may be released during the setting phase of 
composite formation.  For this purpose, 10 mg of washed PLGA particles were 
incubated at 37°C in 1 mL of phosphate-buffered saline (PBS), pH 7.4.  
Supernatant was collected and replaced with fresh PBS every 15 min for the first 
hr, every 30 min for the 2nd hr, every hr for the 3rd and 4th hr, and finally increased 
to every 2 hr for the 6th and 8th hr time points.  Supernatants were filtered (0.45 
µm) and the absorbance measured at 318 nm.   
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5.2.2. Bilayered Calcium Sulfate Composites 
Fabrication of the bilayered composites is illustrated in Figure 5.1.  The 
composites consisted of calcium sulfate hemihydrate (Sigma-Aldrich) as the 
structural matrix.  First, blank CS samples without layers were produced by 
combining 1 g of CS with 800 μL of deionized (DI) water.  The slurry was injected 
into a mold having a diameter of 6.3 mm and a height of 12.6 mm.  The loaded 
mold was placed in a 43°C oven for 24 hr to allow for the CS to completely set.  
To begin formation of bilayered composites, cylindrical cores were 
produced in Teflon molds having a diameter of 4.7 mm and a height of 10 mm.  A 
small, 8 mm long metal peg with a 0.63 mm diameter was fitted precisely in the 
center of the mold, with about 2.5 mm of the peg embedded into the core.  The 
pegs suspended and centered the cores for shell production later.  To make 
blank CS cores, 800 µL of DI water was added to 1 g of CS powder and mixed 
thoroughly in 3 mL non-sterile syringes fitted with a 16 gauge blunt needle.  The 
slurry was loaded into the custom-fabricated Teflon mold and placed in a 43ºC 
oven for 24 hr to set the CS.  For cores loaded with simvastatin, the same 
process was used, however 20 mg of simvastatin (Haouri Pharma-Chem, Inc., 
Edison, NJ) were mixed along with the CS and DI water.  Pegs were removed 
from the cores when they were dried, and the cores were stored at room 
temperature with desiccant until used. 
To form the shell around the cores, another Teflon mold was created with 
cylindrical holes having the diameter of 6.3 mm and a height of 12.6 mm.  The 
base plate was fabricated with 3.5 mm deep holes into which metal pegs were 
securely inserted.  This depth allowed the cores to be positioned precisely in the 
center of the mold, thus allowing the shell to surround the core.  Blank and 
simvastatin-loaded shells were created using the same method described above 
for the cores, where 1 g of CS was mixed with 800 μL of DI water, and in the 
case of simvastatin-loaded shells, 20 mg of drug were directly added.  For 
samples containing metronidazole-loaded PLGA, the particles were added to 
both the blank and simvastatin-loaded shells at either 1 or 10 wt% and then 
mixed with 850 μL DI water in 3 mL syringes fitted with a blunt-tipped needle for 
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easy, consistent filling of the mold.  Using these formulations for the shells, 
bilayered composites were formed by filling the molds about half full.  Next, 
prefabricated cores were quickly dipped in DI water to wet the surface, which 
allowed for smooth coverage of the shell slurry around the core, inserted into the 
mold, and pressed down onto the metal pegs until they stopped.  The pegs 
positioned the cores and held them in place during setting of the shell slurry.  The 
filled mold was placed into a 37°C oven and allowed to dry overnight.  For 
simplification, the different types of samples were given abbreviated names 
(Table 1). 
The shells and cores described had a volume ratio of 50:50.  Two other 
ratios were tested with simvastatin loaded into the shell only (SSBC), core only 
(BSSC), or both layers (SSSC).  These samples were used to demonstrate how 
a change in the volume ratio would affect drug release from the composites.  
Table 2 lists the volume ratios used and the dimensions of the respective core 
and shell components.  Custom molds were created to accommodate the 
different sizes, but the rest of the fabrication process was the same as described 
previously.    
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Figure 5.1. Schematic depicting the process of forming a bilayered CS 
composite.  From left to right: core formation; insertion of core into shell mold; 
final composite showing core encased within a CS shell.  Images are to scale. 
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Table 5.1. Abbreviations for the different sample types fabricated.  Codes are 
read: BSBC » (B)S(B)C » (Loading) in SHELL, (Loading) in CORE. 
 
  
Shell Composition Core Composition Code 
Blank Blank BSBC 
Blank  Simvastatin BSSC 
Simvastatin  Blank SSBC 
Simvastatin  Simvastatin SSSC 
1 wt% PLGA  Blank 1-BSBC 
1 wt% PLGA  Simvastatin 1-BSSC 
1 wt% PLGA & Simvastatin  Blank 1-SSBC 
1 wt% PLGA & Simvastatin  Simvastatin 1-SSSC 
10 wt% PLGA Blank 10-BSBC 
10 wt% PLGA  Simvastatin 10-BSSC 
10 wt% PLGA & Simvastatin  Blank 10-SSBC 
10 wt% PLGA & Simvastatin  Simvastatin 10-SSSC 
No Layer Blank (No Drug) NL 
Note: PLGA particles contained metronidazole. 
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Table 5.2. Shell to core volume ratios and dimensions of the bilayered 
composites 
 
  
Volume 
Ratio 
Shell Height Shell 
Diameter 
Core Height  Core 
Diameter 
50:50 12.6 mm 6.3 mm 10 mm 4.7 mm 
70:30 9.6 mm 4.7 mm 6.2 mm 3.2 mm 
85:15 9.6 mm 4.7 mm 6.2 mm 2.4 mm 
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5.2.3. Composite Microarchitecture 
To monitor the distribution of PLGA particles within the CS shell matrix as 
well as the interface between shell and core, microcomputed tomography 
(microCT) was employed. Using a Scanco Medical μCT-40 scanner, specimens 
were evaluated at high resolution.  Other parameters were set as follows: 156 μm 
increments, 0° angle, 70 kVp, 114 μA, 0.5 mm Al filter, and a voxel size of 8 μm. 
The raw images were qualitatively investigated for particle distribution trends, 
core orientation, and shell-core interaction. In addition, qualitative and 
quantitative assessment of the composites was conducted using a built-in ‘bone 
trabecular morphometry’ analytical tool with a lower threshold level of 130, gauss 
sigma of 3.0, and gauss support of 9. This script created a three-dimensional 
reconstruction that allowed visual assessment of cross-sections through the 
composite and provided the volume percentage of embedded polymeric particles 
and internal voids.  
 
5.2.4. Composite Dissolution 
Destructive testing was used to monitor dissolution of the bilayered 
composites. BSBC, 1-BSBC, and 10-BSBC samples were weighed, placed in 
separate 20 mL scintillation vials containing 12 mL of PBS and incubated on a 
plate shaker at 37ºC. Every 4 d, replicate samples of each type were removed 
and dried at 43ºC overnight. For the remaining samples, the PBS was replaced 
with fresh solution. The dried samples were weighed to determine the amount of 
material remaining, which was then used to calculate the percentage of residual 
mass. 
 
5.2.5. Mechanical Properties 
Compression testing was performed to investigate any effects on 
mechanical properties caused by the layered geometry, simvastatin directly 
loaded into CS as well as the introduction of PLGA particles into the shell of the 
composites.  All samples types listed in Table 1 were evaluated.  Testing was 
accomplished using a Bose ELF 3300 system. Contact surfaces were lightly 
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sanded, if necessary, to create parallel surfaces in contact with the compression 
platens. All samples were loaded at a rate of 0.5 N/sec until failure. Compressive 
modulus (M) and ultimate compressive strength (UCS) were calculated [130]. 
 
5.2.6. Drug Release from Bilayered Composites 
5.2.6.1. Simvastatin Release 
 Release of simvastatin was measured for composites having shell to core 
volume ratios of 50:50, 70:30, and 85:15.  BSBC, BSSC, SSBC, and SSSC 
samples for all volume ratios were prepared using the same simvastatin loading 
described in section 2.2.  Samples were pre-weighed and submerged in PBS.  
Considering the overall size differences between the sample types, different 
volumes of PBS were used to maintain similar fluid volume to composite surface 
area ratios.  To determine suitable sink conditions, sample surface area to 
solution volume ratios  of 50:50 samples was compared to those used in 
previous research [113].  A small pilot study (data not shown) showed that the 
dissolution rate of 50:50 samples remained constant for volumes above 10 mL.  
To avoid saturation of CS or drug in PBS, a larger volume (12 mL) was used for 
the 50:50 samples.  All other samples were placed in 4 mL, similar to previous 
release studies [131].  To determine how simvastatin would be released from 
bilayered composites dissolving in non-sink conditions, 50:50 samples were also 
immersed in 8 mL of PBS.  All samples were incubated at 37°C on a plate 
shaker.  Every 4 d, supernatant was collected and replenished with fresh PBS.  
Collected supernatant was treated with 100% ethanol in a 50:50 volume ratio to 
make sure all simvastatin was in solution.  The mixture was then 0.45 µm-filtered 
and absorbance measured at 240 nm.  
5.2.6.2. Multiple Drug Release 
To investigate the kinetics of metronidazole and simvastatin release from 
bilayered CS composites, samples were pre-weighed, submerged in 12 mL of 
PBS, and incubated at 37°C while on a plate shaker.  Supernatant was collected 
and replenished every 4 d.  Two aliquots from each sample were kept for 
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measurement of metronidazole and simvastatin separately. Metronidazole in 
syringe-filtered (0.45 µm) supernatant was assayed directly using UV 
spectroscopy at 318 nm.  Simvastatin was measured using high performance 
liquid chromatography (HPLC) on a Hitachi Primaide system fitted with a Kinetix 
C18 column (5 μm, 4.6 x 150 mm).  Prior to measurement, supernatant was 
mixed with 5 mM EDTA (pH 8.0) at a 50:50 volume ratio and allowed to sit 
overnight.  EDTA, a common chelating agent, was used to remove calcium ions 
that could precipitate during HPLC analysis.  Next, this mixture was mixed with 
100% ethanol in a 50:50 volume ratio to ensure complete dissolution of the 
poorly soluble simvastatin.  The final sample composition was 25% supernatant, 
25% EDTA, and 50% ethanol.  A 70:30 (acetonitrile : DI water + 0.01% 
trifluoroacetic acid) isocratic mobile phase at a flow rate of 1 mL per minute was 
used.  Simvastatin was detected at 240 nm.   
 
5.2.7. Statistics 
Statistical analysis of the results was conducted using either a two-tailed 
unpaired t-test or one-way ANOVA.  As appropriate, a Tukey-Kramer multiple 
comparison post hoc test was implemented.  Linear regression was performed 
on sustained release profiles and the calculated slopes compared for significant 
differences using a two-tailed t-test.  Differences between groups were 
considered to be significant with p-values <0.05.   
 
5.3. Results 
5.3.1. Metronidazole-loaded PLGA Particles 
Metronidazole-loaded PLGA particles alone were first evaluated to 
determine how well the polymer controlled drug release.  According to the results 
in Figure 5.2, metronidazole was released steadily during the first 3 hr at a rate of 
about 4 μg per minute.  Only about 8% of the drug was released during the first 
hr.  After 3 hr, 30% of the total loading of metronidazole had been released.  
From this point forward, the release of drug from the particles slowed, with 
roughly 35% of the loaded metronidazole released after 6 hr.  
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5.3.2. Composite Microarchitecture 
5.3.2.1. Qualitative Evaluation 
MicroCT images showed the CS cores embedded within the layered 
composites and their interaction with the CS shells, as well as the distribution of 
PLGA particles embedded in the shells (Figure 5.3). For comparison, results for a 
CS sample without layers (NL) are included.  Minor defects (bubbles and other 
discontinuities) were found throughout the CS matrix in all samples.  These 
defects were nearly spherical in nature and, thus, easily distinguishable from 
PLGA particles, which were irregularly shaped.  The blank (drug-free) layered 
samples, BSBC, showed the CS core embedded within the CS shell and oriented 
parallel to the outer walls.   The distribution of 1 wt% PLGA particles in the shells 
of 1-BSBC samples appeared to be uniform but sparse (Figure 5.3, top right).  In 
10-BSBC samples with 10 wt% loading of particles in the shells, there was a 
uniform but more frequent distribution of particles throughout the CS shell (Figure 
5.3, bottom right). Similar to BSBC, both 1-BSBC and 10-BSBC had cores that 
were embedded in the center of the composite with a parallel orientation to the 
outer surface.  Additionally, all layered samples had some minor defects located 
at the shell/core interface, with most of these discontinuities occurring near the 
top and bottom of the samples.  
5.3.2.2. Quantitative Evaluation 
 Morphometric analysis was conducted to better assess the overall 
microarchitecture of bilayered CS samples.  As shown in Figure 5.4, the average 
volume percentage of voids in NL samples (0.96%) was significantly lower than 
that for all others (p<0.001).  Furthermore, the particle content of 10-BSBC 
samples, 7.59%, was significantly higher (p<0.001) than that of both BSBC and 
1-BSBC.  Percentages for BSBC (3.30%) and 1-BSBC (4.52%) were not 
significantly different.  
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5.3.3. Composite Dissolution 
Loading 1 wt% of PLGA particles into the shells of bilayered composites 
did not have a significant effect on the dissolution rate (-3.1%/d) (Figure 5.5). 
Increasing the loading to 10 wt% PLGA, however, significantly increased the 
dissolution rate to -3.43%/d (p<0.001), even though the time for complete 
dissolution differed by only about 4 d. 
 
5.3.4. Mechanical Properties of Layered CS 
 Fabrication of layered structures significantly affected the mechanical 
properties of CS composites (Figure 5.6).  The ultimate compressive strength of 
NL (5.40±0.38 MPa) samples was not significantly higher than that of BSSC 
(4.14±0.75 MPa) and 1-BSBC (4.33±0.72 MPa), but it was significantly greater 
than that for BSBC (3.80±0.46 MPa, p<0.01) and all other bilayered samples 
(p<0.001) (Figure 5.6A).  Within subgroups for PLGA particle loading, the 
strength of 1-BSBC (4.33±0.72 MPa) was significantly higher than both 1-SSSC 
(3.03±0.2 MPa) and 10-BSSC (3.03±0.4 MPa) (p<0.05).  There were no other 
significant differences seen for layered samples, both loaded with PLGA and 
without.   
The compressive elastic modulus of NL (712±139.6 MPa) was significantly 
higher (p<0.001) than that for SSBC (250±37.6 MPa), 1-BSBC (172±96.9 MPa), 
1-SSSC (162±70.4 MPa), 10-BSBC (237±84.2 MPa), 10-BSSC (154±58.4 MPa), 
10-SSBC (216±87.8 MPa), and 10-SSSC (184±29.6 MPa) bilayered samples 
(Figure 5.6B).  The average modulus of the blanks was also significantly greater 
than those of SSSC (306±157.6 MPa, p<0.01) and 1-SSBC (391±282 MPa, 
p<0.05).  BSSC (495±184MPa) samples had a significantly higher (p<0.05) 
modulus than did 1-BSBC , 1-SSSC, and 10-BSSC.  There were no other 
significant differences between layered samples and their subgroups.  
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Figure 5.2.  Cumulative release of metronidazole from 150-250 μm PLGA 
particles. Data are mean ± standard deviation (n=3). 
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Figure 5.3. Representative microCT images of CS/PLGA composites: raw X-ray 
slices and cross-sections of 3D reconstructions. Closed arrows mark bubbles, 
and open arrows with circles indicate PLGA particles. Scale bars denote 1 mm.    
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Figure 5.4. Volume percentage of voids/particles in CS/PLGA composites 
determined by microCT.  Data are mean ± standard deviation (n=5). Symbols (*) 
indicates significant differences (p<0.001).   
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Figure 5.5.  Mass loss profiles for bilayered blank CS and composites with 1 and 
10 wt% PLGA loaded into the shells. Data are mean ± standard deviation (n=3). 
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A.  
B.  
Figure 5.6. Mechanical properties of CS/PLGA composites with directly loaded 
simvastatin: A) ultimate compressive strength and B) compressive modulus. Data 
are mean ± standard deviation (n=5). Symbols indicate significant differences: 
p<0.001 (*), p<0.01 (#), and p<0.05 (Δ). 
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5.3.5. Drug Release from Bilayered Composites 
5.3.5.1. Simvastatin Release 
To demonstrate temporally controlled release of simvastatin using 
bilayered composites, several experiments were conducted using different shell 
to core volume ratios.  Figure 5.7A shows the cumulative release of simvastatin 
from composites that had an 85:15 shell to core volume ratio.  The sustained 
release of drug from samples with simvastatin loaded into both shell and core 
(SSSC), 0.055 mg/d, was significantly faster (p<0.001) than for SSBC (0.043 
mg/d) and SSBC+BSSC (0.046 mg/d).  Minimal drug loaded into the core only 
(BSSC) was released during the first 24 d.  From that point until the samples 
dissolved, however, release of simvastatin from CS cores increased to 18 μg/d, 
whereas release from SSBC samples was finished.  The total amount of 
simvastatin released from BSSC (shell) and SSBC (core) samples was 
0.24±0.05 mg and 1.19±0.01 mg, respectively.  The rate of release from BSSC 
was significantly slower than that for both SSSC (p<0.05) and SSBC+BSSC 
(p<0.01).  
Figure 5.7B shows the results for simvastatin released from composites 
consisting of 70% shell volume and 30% core volume.  Over the first 20 d, the 
drug release rate from SSBC (0.046 mg/d) was significantly faster (p<0.01) 
compared to 0.041 mg/d for SSSC.  Little to no drug was released from BSSC 
samples during the first 20 d, followed by an upward shift to a rate of 0.022 mg/d, 
which was significantly slower than the rates for both SSSC and SSBC+BSSC 
(p<0.01).  For BSSC samples, 0.32±0.03 mg of drug was released.  After 20 
days of simvastatin release from SSBC samples, the shells had completely 
dissolved and released 1.30±0.07 mg of simvastatin.  
The results for release of simvastatin from composites with a 50:50 shell 
to core volume ratio are depicted in Figure 5.7C.  For the first 16 d of the 
experiment, the rate of release from SSBC composites, 0.095 mg/d, was 
significantly slower (p<0.05) than that for SSSC (0.13 mg/d) and SSBC+BSSC 
(0.12 mg/d).  During the same period, a small amount of drug was released from 
BSSC at a slow rate of 0.025 mg/d.  After 16 d and until the composites 
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dissolved, the rate of drug release from SSBC samples gradually slowed as the 
shell finished dissolving, a trend similar to what was observed in both Figures 
5.7A and 5.7B.  A total of 1.52±0.3 mg of drug was released from the shell.  At its 
peak, the rate of release from BSSC samples, 0.10 mg/d, was not significantly 
different from the rates observed for SSSC and SSBC+BSSC samples, ultimately 
releasing a total 1.44±0.24 mg of simvastatin.   
The total amount of simvastatin released from the cores (BSSC) for 50:50 
(1.44±0.24 mg) samples was significantly different (p<0.001) than that for 
samples with either a 70:30 (0.32±0.03 mg) or 85:15 (0.24±0.05 mg) shell to core 
volume ratio.  There was no significant difference in the total drug release 
between the 70:30 and 85:15 BSSC samples.  For 50:50 SSBC samples, the 
total amount released (1.52±0.3 mg) from the shells was significantly different 
(p<0.001) than for 70:30 SSBC (1.30±0.07 mg) and 85:15 SSBC (1.19±0.1 mg) 
samples.  In addition, the total amount of drug released from 70:30 SSBC 
samples was significantly different than from 85:15 SSBC samples (p<0.01).  
When comparing the total amount of drug released when SSBC and BSSC 
results are combined (SSBC+BSSC) to the total amount of drug released from 
SSSC samples, SSBC+BSSC specimens with an 85:15 shell to core volume ratio 
had a total combined release that was significantly lower (p<0.01) than the total 
amount of simvastatin released from the SSSC with the same volume ratio.   
 By reducing the volume of PBS from 12 mL to 8 mL, the dissolution time 
of samples having a 50:50 shell to core ratio was doubled (Figure 5.8).  During 
the first 32-36 d of incubation, simvastatin was released from both SSSC and 
SSBC samples at a rate of 0.074 mg/d and 0.077 mg/d, respectively.  Also, a 
small amount of drug from BSSC samples was released during the same time 
frame at a rate of 0.009 mg/d.  From day 36 until the end of the experiment (68 
d), the rate for the SSSC samples continued steadily, however the rate of release 
from SSBC decreased to zero around 48 d.  Additionally, the rate of release from 
BSSC samples increased to 0.051 mg/d and remained at this rate until the 
samples finished eroding.  
87 
 
A.  
B.  
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C.  
Figure 5.7.  Cumulative release of simvastatin from bilayered samples having 
different shell to core volume ratios: (A) 85:15; (B) 75:25; and (C) 50:50.  Data 
are mean ± standard deviation (n=5). 
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 Figure 5.8.  Cumulative release of simvastatin from bilayered samples incubated 
below sink conditions.  The samples tested had a 50:50 shell to core volume 
ratio.  Data are mean ± standard deviation (n=5). 
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5.3.5.2. Multiple Drug Release 
Figure 5.9 shows results for release of metronidazole from PLGA particles 
embedded in CS shells as well as the release of simvastatin directly loaded in 
the shell or core of bilayered composites.  The samples used for this experiment 
had a 50:50 shell to core volume ratio.  Based on this ratio and the dissolution 
results presented in Figure 5.5, the shell and core portions of the composites 
were predicted to dissolve completely in 14-16 d of the 28-32 d dissolution period 
for the complete composite.  For composites with 1 wt% PLGA particles 
embedded in CS, a large amount of metronidazole (65%) was initially released 
from the shells during the first 4 d at a rate of 16.3%/d (Figure 5.9A).  After the 
initial burst of metronidazole, the release of drug slowed to a rate of 4.0%/d and 
continued to slowly decay to zero until the shells completely dissolved.  
Composites with 10 wt% PLGA particles showed a similar burst of metronidazole 
during the first 4 d, with as much as 55% of the total drug released (Figure 5.9B).  
The rate of release of metronidazole decayed from 13.7%/d through the first 4 d, 
to 6.7%/d from days 4-8, and finally down to 0% by d 12 of the release.  The 
results in Figure 5.9 were normalized based on the amount of drug loaded into 
the respective layer rather than the complete composite.  This allowed for direct 
comparison of the temporal release observed between metronidazole and 
simvastatin.  When simvastatin was loaded into only the shell for 1 wt% and 10 
wt% PLGA composites, metronidazole was initially released at a higher rate than 
simvastatin (2-6.3%/d).  Because of the slow initial rate of simvastatin release, a 
short lag in the release profile developed, creating separation from the 
metronidazole profile and allowing for simvastatin to be released for up to 8 d 
longer.  When the drugs were separated by keeping metronidazole-containing 
PLGA particles in the shell and loading simvastatin in only the core, 80-90% of 
the metronidazole was released over approximately 12 d before trace amounts of 
simvastatin were detected.  After 16 d, the shells had completely dissolved, and 
metronidazole was no longer detected.  In addition, the majority of simvastatin, 
isolated to only the core, was released starting after 12 d.  Due to the layers 
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separating the two drugs, a sequential release was observed with all 
metronidazole drug released prior to simvastatin.   
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A.  
B.  
Figure 5.9.  Cumulative release of simvastatin and metronidazole from bilayered 
composites. Normalized profiles of directly loaded simvastatin and metronidazole 
loaded into PLGA particles released from composites with (A) 1 wt% and (B) 10 
wt% PLGA particles loaded in shells.  Data are mean ± standard deviation (n=5).  
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5.4. Discussion 
5.4.1. Metronidazole-loaded PLGA Particles 
In previous studies, two types of PBAE hydrogel particles were used as 
drug delivery vehicles [113, 131].  Because bilayered CS composites are being 
developed as tunable implants with the idea of being a ‘plug and play’ system, 
PLGA was introduced to help demonstrate this versatility.  The use of different 
polymers could allow for carrier particles to be matched with different drug 
properties, such as size and solubility.  A previous study showed that loading a 
small hydrophilic drug into carrier particles prior to embedding into a CS matrix 
significantly reduced the burst release witnessed when the drug was directly 
loaded into CS [131].  Biodegradable PLGA microparticles were used in the 
present study to assist with the sustained release of metronidazole from 
bilayered composites.  Because the particles were exposed to water during the 
setting phase of CS, a release study was conducted using a larger volume of 
water than present during composite formulation to monitor the potential for 
premature release of drug from PLGA.  No initial burst of drug was observed, 
indicating that the majority of the drug was contained within the PLGA 
microparticles during the formation of the composites.   
 
5.4.2. Composite Microarchitecture 
Qualitative assessment of the morphology of bilayered composites 
showed good distribution of PLGA microparticles embedded into CS shells at 1 
and 10 wt%.  The initial CS slurry was kept sufficiently fluid to prolong the 
working phase and allow for easy filling of the molds yet viscous enough to 
suspend PLGA particles during the setting phase.  This trend has been shown in 
previous research in which hydrogel particles were uniformly distributed 
throughout a CS matrix using similar powder to liquid volume ratios [113].  
Another study, showed the exposure of particles at or near the surface before 
dissolution followed the pitting of CS resulting from the release of particles from 
those locations after a short duration submerged in PBS [131].  With the aid of 
small, metallic pegs, which were removed after fabrication, preformed blank and 
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simvastatin-loaded cores were positioned in the center of the composites.  Small 
defects were observed along the shell/core boundary.  Many of these were air 
bubbles trapped as the CS set.  Larger bubbles that appeared to accumulate 
near one end of the samples along the shell/core interface were most likely 
caused by an air pocket created when the cores were pressed into CS slurry.   
 Quantitative measurements assessed the particle volume fraction of 
bilayered CS composites.  Although a significant increase in porosity was seen 
between samples containing 1 wt% and 10 wt% PLGA, the difference was not 
10-fold.  This lack of separation could be due to other defects, such as air 
pockets found along the shell/core interface.  The script used to calculate the 
porosity is limited to only distinguishing between what is solid and what is not.  
The introduction of bubbles adds error to the calculations because these 
imperfections show up as radiolucent spaces similar to PLGA particles.  
Comparing the solid and layered samples demonstrates that defects strongly 
influenced on the porosity calculations. 
 
5.4.3. Composite Dissolution 
Calcium sulfate is a dense material that dissolves via surface erosion [33, 
113].  Although the embedded PLGA particles were distributed throughout the 
CS matrix, they did not appear to be interconnected, which otherwise would have 
allowed for fluid to seep into the composite.  During erosion, closed pockets with 
PLGA particles near the surface were exposed, releasing the polymer particles 
and increasing the surface area for further dissolution.  Consequently, as the 
composites dissolved and PLGA particles were released, the surface area to 
volume ratio increased, allowing for faster dissolution of CS. Furthermore, 
because embedded PLGA particles did not change the dissolution characteristics 
of CS, the shorter lifespan when 10 wt% particles were added was related to the 
smaller overall volume of CS per sample that needed to dissolve.  These trends 
have also been witnessed in a previous study in which dissolution of CS was 
observed after hydrogel particles were uniformly distributed throughout the 
composite [113].  Thus, the presence of polymer particles, even having different 
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chemistries, affected only the duration of dissolution, depending on the amount of 
particles loaded, and not the nature of the dissolution process itself.   
  
5.4.4. Mechanical Properties of Layered CS 
To be a suitable alternative to autologous bone, the ideal synthetic 
material would have characteristics similar to those of tissue at the implantation 
site.  CS has been described as having properties being similar to cancellous or 
trabecular bone [38].  Investigating the mechanical properties of human 
trabecular bone from the mandible, Misch et al. measured an ultimate 
compressive strength of 3.9 ± 2.7 MPa and elastic modulus of 96.2 ± 40.6 MPa 
[132]. The introduction of a bilayered geometry significantly affected properties 
compared to solid CS samples, with up to a 44% and 78% reduction in the 
strength and elastic modulus, respectively.  Note, however, that the properties of 
the layered composites were comparable to those of trabecular bone.  The 
decrease in strength compared to the samples without layers could be due to the 
small air pockets along the shell/core interface acting as discontinuities within the 
composite, both at the interface parallel to the central axis of the cylinder as well 
as at the ends of the core.  These stress concentrators contributed to a 17-44% 
decrease in the overall strength of the composites.  The addition of either 1 or 10 
wt% PLGA particles to CS shells did not have an effect when compared to blank 
bilayered samples.  In previous research, as much as a 50-60% reduction in 
strength was seen following the addition of 10 wt% of gel particles to the 
monolithic CS matrix [113].  In the present study, the PLGA particles were 
isolated to only the shell of the composites.  Also, the presence of a solid blank 
core may have provided reinforcement for the composite, which may allow a 
greater range of PLGA particle loading that would provide greater control over 
the drug dose within the composites.   
 The loading of simvastatin directly into the shell, core, or both layers 
generally did not significantly affect the strength of the bilayered composites, 
even though isolated differences were observed (1-BSBC versus 1-SSSC and 
10-BSSC).   In another experiment conducted by Orellana et al., loading of 
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simvastatin directly into monolithic CS did not have a significant effect on the 
strength of the samples [131].  Another group determined that up to 10% loading 
of simvastatin into calcium phosphate samples did not significantly affect the 
compressive strength [118].  The present study had a lower loading of 
simvastatin (i.e., 2 wt%), however.  Thus, direct loading of simvastatin does not 
affect the overall strength of different materials.      
 
5.4.5. Drug Release from Bilayered Composites 
The layered geometry used for the CS samples provided a unique 
platform for achieving a customizable sequential release of therapeutic agents.  
Loading of PLGA microparticles into the CS matrix allows for further tailoring of 
drug release.   
5.4.5.1. Simvastatin Release 
The present experiments were designed to demonstrate how the release 
of simvastatin can be tailored depending on which layer the drug was loaded in, 
whether it was the shell only, core only, or both.  Furthermore, to illustrate the 
ability to adjust the duration or even the delay of drug release from either the 
shell or core, the shell to core volume ratio was altered.  However, there were 
limitations to how much the volume ratio could be adjusted.  For instance, the 
50:50 shell to core ratio was considered the maximum.  With the present 
dimensions, increasing the core volume beyond this point would create a thin 
and unstable shell.  On the other hand, if the ratio was made so the shell would 
be greater than 85% of the total volume, the local concentration of drug released 
from the core could be too low to be therapeutically relevant.   
For all of the release profiles that had simvastatin loaded in only the cores, 
there was a small amount of drug released from the start of composite 
dissolution up to when the core was completely exposed.  Because the cores 
were suspended using a small metal peg that was later removed after the 
samples were fabricated, the hole that remained may have been large enough to 
allow a noticeable, but statistically insignificant, amount of simvastatin to be 
released.   
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In addition to investigating the effects of adjusting the shell to core volume 
ratio, the volume of PBS used for the release study was reduced from 12 mL to 8 
mL.  Because of the possible diverse environments in various implantation sites, 
it is likely for the implant to encounter different fluid volumes and/or turnover 
rates that may not allow for sink conditions.  A small study demonstrated how 
release of simvastatin would change under non-sink conditions.  To conduct the 
comparison, the 50:50 volume ratio was used.  Interestingly, even with the 
reduction in the volume of PBS to 8 mL, the transition after shell depletion to core 
only erosion occurred around the halfway point, similar to the results seen under 
sink conditions.  In previous work, the effects of fluid volume on the dissolution of 
CS were investigated [113].  It was determined that the change in volume of fluid 
or even the turnover rate could have a large effect on the dissolution of CS [113].  
The duration of drug release can be greatly prolonged (doubled in the present 
study) using different fluid volumes.  McLaren et al. also observed a large 
difference in the rate of drug release from calcium sulfate pellets when the fluid 
was completely refreshed at each time point versus exchanging only a fraction of 
the fluid volume [133].  In the present study, although the rate of release slowed, 
the mechanism of drug release remained dependent on dissolution of CS.  This 
could allow for tailoring of drug loading and/or the sample geometry according to 
the physiological conditions expected at the implant site. 
5.4.5.2. Multiple Drug Release 
A multiple drug release study was conducted to investigate the release 
kinetics of bilayered composites loaded with an antimicrobial agent and an 
osteogenic agent.  Findings for samples with metronidazole in PLGA particles 
and simvastatin directly loaded into CS demonstrated sequential release.  
Polymeric particles loaded with metronidazole and embedded into the shell were 
exposed as CS experienced surface erosion, and sustained release of the drug 
occurred as the PLGA particles subsequently degraded.  Release from both 1 
and 10 wt% particles embedded into the CS shell was sustained until the shell 
portion of the bilayered composites completely dissolved.  Controlled release of 
metronidazole from PLGA microspheres after an initial burst has been described 
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as a possible treatment for periodontal disease [134].  By embedding particles 
into a CS matrix, the release of metronidazole was controlled throughout the first 
16 d of the present study.  In addition, previous research has demonstrated that 
drug-loaded hydrogel particles uniformly distributed throughout a CS matrix 
allowed for a controlled release of drug, which only occurred due to the 
breakdown of particles exposed at the surface of the dissolving composite [113, 
131].   
With the intended use of these composites as a grafting substitute for 
alveolar bone augmentation, the oral cavity presents challenges for proper tissue 
regeneration due to the environment being rich with bacteria that can colonize 
natural and synthetic substrates.  Thomas and Puleo described the implications 
of infection and inflammation in periodontal disease and tissue regeneration 
[135]. Currently, the standard treatment for infected periodontal defects has 
antimicrobial agents being administered, either systemically or locally, prior to 
implantation of grafting material, which only delays the overall recovery of lost 
tissue [14, 119, 123].  Administration of antimicrobial agents allows for better 
bone formation.  Chen et al. investigated the effects of two different growth 
factors in a chronically infected bony defect in rat femurs [136].  Although some 
healing occurred in the infected sites, the extent of bone formation was greater 
with the systemic administration of antibiotics [136]. To further enhance the 
process of fighting infection and then regenerating lost tissue, release of an anti-
bacterial agent from the graft starting at the time of implantation may prove 
beneficial to help reduce the overall healing time.   
Many studies have investigated dual purpose implantable scaffolds, but 
none have employed a concentric cylindrical CS system as described in the 
present studies.  Reis et al. developed drug-free, bilayered membranes 
comprising a continuous outer layer of PLGA with a porous calcium phosphate 
inner layer for the regeneration of lost periodontal tissue [137]. For infected sites, 
Nguyen et al. developed a co-culture model using methicillin-sensitive 
Staphylococcus aureus and mouse bone marrow stromal cells to investigate the 
dual effects of an antibiotic, vancomycin, along with bone morphogenetic protein-
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2 (BMP-2) [119].  Separately, the two agents were not effective, but when 
delivered together, the needed concentration of vancomycin was significantly 
reduced, suggesting that lower, non-toxic doses could be used [119].  An in vivo 
study in which vancomycin and BMP-2 were delivered simultaneously from a 
biodegradable polyurethane scaffold demonstrated that bone formation could be 
regenerated within an infected defect [138].  However, these systems release the 
drugs simultaneously.  Considering the intent for the current device to help 
streamline the existing treatment process, it was encouraging to see 
metronidazole released before simvastatin, even when loaded into the shell 
together.  The difference in the release kinetics can be explained primarily by the 
way the two drugs were loaded.  Previous work has shown that release of drug 
from polymer particles embedded into a CS matrix had a rapid, initial burst 
followed by decay in the rate of release [113, 131].  The lower rate is attributed to 
the decrease in surface area as CS degrades, leading to a smaller volume of 
particles exposed at the surface over time [113, 131].  Simvastatin, on the other 
hand, is directly mixed with CS during sample formation, and due to the 
hydrophobic nature of the drug, it does not become segregated to the surface 
during the setting of CS.  The release of simvastatin is, therefore, governed by 
the surface erosion characteristics of CS, which were shown to be linear.  This 
allowed for a near constant rate of release of simvastatin. These differences in 
release kinetics between the two drugs and their means of loading allowed for 
enough separation for all the metronidazole to be released 4 d sooner than 
simvastatin.  When simvastatin was loaded into only the core while PLGA 
particles loaded with metronidazole remained in the shell, there was a much 
greater lapse in time for a fully separated sequential release to occur, which may 
be useful for mimicking the clinical sequence of events for treating infection and 
subsequently restoring lost or damaged tissue.       
    
5.5. Conclusion 
In the present study, novel bilayered CS composites were investigated for 
their ability to provide tailored release of therapeutic agents as well as a 
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sequential release of different drugs.  Such a system may be useful as a bone 
graft substitute for treating infected bony defects, e.g., periodontal pockets.  
Although the shell and core geometry reduced mechanical strength of the 
composites, the properties were similar to those for mandibular trabecular bone.  
This may be an important trait that could allow for these implants to better mimic 
the surrounding target tissue being treated.  Changing the shell to core volume 
ratio dictates the duration of drug release from each layer.  When metronidazole 
and simvastatin were loaded together in the shell or in separate layers, temporal 
separation of the two drugs was achieved.  Being able to tune such a system 
may help streamline the multiple steps needed to regenerate tissues more 
efficiently.   
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Chapter 6:  Summary and Conclusions 
 
Calcium sulfate based bone graft substitutes were developed not only as 
space-making implants for proper bone regeneration, but also to have the ability 
to control the release of multiple agents to aid in the healing process.  CS 
composite samples fabricated with varying amounts (1 or 10 wt%) and sizes (53-
150 or 150-250 µm) of embedded A11 PBAE gel particles was shown, using 
MicroCT, to be uniformly distributed throughout CS.  During dissolution CS 
samples degraded via surface erosion, with the amount of gel particles (i.e. 10 
wt% gel particles) having only a small but significant effect on the dissolution rate 
(4% vs. 5% per day).  Compression analysis determined that the amount, but not 
the size, of gel particles had a significant effect on the overall mechanical 
strength of the composite.  The swelling and rate of degradation of A11 PBAE 
gels alone occurred in less than 24 hours.  This turned out to be an important 
characteristic that aided in the controlled release of curcumin from A11 PBAE 
gels embedded in a CS matrix.  
The versatility of these implants to release a broad range of therapeutic 
agents was examined with the intention that drugs could be chosen for patient 
specific cases.  Whereas sustained release of directly loaded simvastatin was 
achieved, direct loading of small amounts of lysozyme resulted in highly variable 
release.  Direct loading of a larger amount of protein generated a large burst, 
65% of total loading, followed by sustained release of that protein.  Release of 
lysozyme from 1 wt% H6 PBAE particles embedded into CS was more 
controllable than when directly loaded, and for 10 wt% of protein-loaded H6 
PBAE particles, a higher burst was followed by sustained release, comparable to 
the results for the high direct loading.  Compression testing determined that 
incorporation of directly loaded drug or drug-loaded H6 PBAE particles 
weakened CS. In particular, H6 PBAE particles had a significant effect on the 
strength of the composites, with a 25% and 80% decrease in strength for 1 wt% 
and 10 wt% particle loadings, respectively.  These results were similar to those 
witnessed for the composites loaded with A11 PBAE particles.  These CS-based 
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composites demonstrated the ability to sustainably release both macromolecules 
and small molecules, supporting the potential for these implants to release a 
range of bioactive agents. 
The concept of further tailoring the drug release was examined by creating 
a bilayered system that could allow for more complex release kinetics, as well as 
the release of multiple therapeutic agents.  Bilayered composite samples having 
a shell and core geometry were fabricated with varying amounts (1 or 10 wt%) of 
metronidazole-loaded PLGA particles embedded in the shell and simvastatin 
directly loaded into either the shell, core, or both. MicroCT images showed the 
overall layered geometry as well as homogenous distribution of PLGA within the 
shells.  Dissolution studies, similar to those conducted for the composites with 
A11 PBAE, demonstrated that the amount of PLGA particles (i.e., 1 vs. 10 wt%) 
had a small but significant effect on the erosion rate (3% vs. 3.4% per day).  
Mechanical testing determined that introducing a layered geometry had a 
significant effect on the compressive strength, with an average reduction of 35%.  
Sustained release of simvastatin directly loaded into CS demonstrated that 
changing the shell to core volume ratio dictated the duration of drug release from 
each layer.   When loaded together in the shell or in separate layers, sequential 
release of metronidazole and simvastatin was achieved.  By introducing a 
tunable layered geometry capable of releasing multiple drugs, CS-based bone 
graft substitutes could be tailored in order to help streamline multiple steps 
needed to regenerate tissue in infected defects.   
 Overall, this dissertation illustrated the development of CS-based synthetic 
bone grafts that could be suitable alternatives to ‘gold standard’ approaches.  
Through controlled release of bioactive agents, CS-based implants have the 
potential to greatly enhance their effectiveness as bone grafts.  In addition, the 
introduction of a tailorable layered geometry would allow for CS-based bone graft 
substitutes to be further optimized in order to help streamline the steps during the 
healing and regenerative process of compromised bone tissue within the oral 
cavity.   
Copyright © Bryan Richard Orellana 2014  
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